View Filing Data

Print Document View Excel Document

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2011	Feb. 17, 2012	Jun. 30, 2011
Document and Entity Information [Abstract]
Entity Registrant Name	PDL BIOPHARMA, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		139,875,399
Entity Public Float			$ 818,628,832
Amendment Flag	false
Entity Central Index Key	0000882104
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Dec. 31, 2011
Document Fiscal Year Focus	2011
Document Fiscal Period Focus	FY

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2011	Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 168,544,000	$ 211,574,000
Short-term investments	42,301,000	34,658,000
Receivables from licensees	600,000	469,000
Deferred tax assets	10,054,000	19,902,000
Prepaid and other current assets	12,014,000	18,060,000
Total current assets	233,513,000	284,663,000
Property and equipment, net	22,000	80,000
Long-term investments	17,101,000	1,997,000
Long-term deferred tax assets	11,481,000	22,620,000
Other assets	7,354,000	7,306,000
Total assets	269,471,000	316,666,000
Current liabilities:
Accounts payable	528,000	2,540,000
Accrued legal settlement	27,500,000	65,000,000
Accrued liabilities	11,609,000	7,204,000
Current portion of non-recourse notes payable	93,370,000	119,247,000
Total current liabilities	133,007,000	193,991,000
Convertible notes payable	316,615,000	310,428,000
Non-recourse notes payable		85,023,000
Other long-term liabilities	24,122,000	51,406,000
Total liabilities	473,744,000	640,848,000
Commitments and contingencies (Note 11)	0	0
Stockholders' deficit:
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 250,000 shares authorized; 139,680 and 139,640 shares issued and outstanding at December 31, 2011 and 2010, respectively	1,397,000	1,396,000
Additional paid-in capital	(161,750,000)	(87,373,000)
Accumulated other comprehensive income (loss)	(1,885,000)	3,219,000
Accumulated deficit	(42,035,000)	(241,424,000)
Total stockholders' deficit	(204,273,000)	(324,182,000)
Total liabilities and stockholders' deficit	$ 269,471,000	$ 316,666,000

Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2011	Dec. 31, 2010
Preferred stock par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000	10,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	250,000	250,000
Common stock, shares issued	139,680	139,640
Common stock, shares outstanding	139,680	139,640

Condensed Consolidated Statements Of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Revenues:
Royalties	$ 351,641	$ 343,475	$ 305,049
License and other	10,400	1,500	13,135
Total revenues	362,041	344,975	318,184
Operating expenses:
General and administrative	18,338	41,396	21,064
Legal settlement		92,500
Total operating expenses	18,338	133,896	21,064
Operating income	343,703	211,079	297,120
Non-operating expense, net
Gain (loss) on retirement or conversion of convertible notes	(766)	(17,648)	1,518
Interest and other income, net	593	468	1,004
Interest expense	(36,102)	(43,529)	(19,357)
Total non-operating expense, net	(36,275)	(60,709)	(16,835)
Income before income taxes	307,428	150,370	280,285
Income tax expense	108,039	58,496	90,625
Net income	$ 199,389	$ 91,874	$ 189,660
Net income per share
Basic (in Dollars per share)	$ 1.43	$ 0.73	$ 1.59
Diluted (in Dollars per share)	$ 1.15	$ 0.54	$ 1.07
Weighted average shares outstanding
Basic (in Shares)	139,663	126,578	119,402
Diluted (in Shares)	177,441	178,801	184,400

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Cash flows from operating activities
Net income	$ 199,389	$ 91,874	$ 189,660
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of convertible notes offering costs	5,386	1,682	2,159
Amortization of non-recourse notes offering costs	4,533	7,238	1,256
Other amortization and depreciation expense	1,405	330	991
Loss (gain) on retirement or conversion of convertible notes	766	17,648	(1,518)
Stock-based compensation expense	387	662	821
Tax benefit (expense) from stock-based compensation arrangements	(120)	12,818	64,140
Net excess tax benefit from stock-based compensation		(12,924)	(70,610)
Deferred income taxes	31,217	(5,677)	10,242
Changes in assets and liabilities:
Receivables from licensees	(131)	581	12,450
Prepaid and other current assets	(199)	1,445	(4,903)
Other assets	(6,639)	182
Accounts payable	(2,012)	2,170	(1,347)
Accrued legal settlement	(37,500)	65,000
Accrued liabilities	239	(26,229)	(16,387)
Other long-term liabilities	(26,939)	27,500
Net cash provided by operating activities	169,782	184,300	186,954
Cash flows from investing activities
Purchases of investments	(74,744)	(46,668)
Maturities of investments	50,696	9,772	15,000
Purchase of property and equipment			(39)
Release of restricted cash			3,469
Net cash provided by (used in) investing activities	(24,048)	(36,896)	18,430
Cash flows from financing activities
Retirement of convertible notes	(133,851)	(108,247)	(69,953)
Repayment of non-recourse notes	(110,900)	(95,730)
Net proceeds from the issuance of convertible notes	149,712	82,039
Net proceeds from the issuance of non-recourse notes			285,746
Purchase of call options	(20,765)
Proceeds from issue of warrants	10,868
Cash dividends paid	(83,828)	(130,043)	(319,020)
Excess tax benefit from stock-based compensation		12,924	70,610
Proceeds from issuance of common stock, net of cancellations			1,402
Net cash used in financing activities	(188,764)	(239,057)	(31,215)
Net increase (decrease) in cash and cash equivalents	(43,030)	(91,653)	174,169
Cash and cash equivalents at beginning of the year	211,574	303,227	129,058
Cash and cash equivalents at end the year	168,544	211,574	303,227
Supplemental cash flow information
Cash paid for income taxes	83,000	69,000	29,258
Cash paid for interest	$ 25,627	40,622	$ 11,552
Supplemental disclosures of non-cash financing activities
Conversion of convertible notes		$ 111,680

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Total
Balance at December 31, 2008 at Dec. 31, 2008	$ 1,193	$ 169,196	$ (522,958)		$ (352,569)
Balance at December 31, 2008 (in Shares) at Dec. 31, 2008	119,304,566
Issuance of common stock under employee benefit plans, net	$ 2	1,400			1,402
Issuance of common stock under employee benefit plans, net (in Shares)	218,319
Stock-based compensation expense for employees		773			773
Stock-based compensation expense for consultants		48			48
Tax benefit from employee stock options		64,140			64,140
Dividends declared		(319,407)			(319,407)
Comprehensive income:
Net income			189,660		189,660
Balance at end of Period at Dec. 31, 2009	$ 1,195	(83,850)	(333,298)		(415,953)
Balance at end of Period, shares (in Shares) at Dec. 31, 2009	119,522,885
Issuance of common stock under employee benefit plans, net	$ 1	(1)
Issuance of common stock under employee benefit plans, net (in Shares)	148,198
Stock-based compensation expense for employees		662			662
Tax benefit from employee stock options		12,818			12,818
Dividends declared		(129,677)			(129,677)
Comprehensive income:
Change in unrealized gains and losses on investments in available-for-sale securities, net of tax				$ (1)	(1)
Change in unrealized gains on cash flow hedges, net of tax				3,220	3,220
Total comprehensive income					95,093
Net income			91,874		91,874
Balance at end of Period at Dec. 31, 2010	$ 1,396	(87,373)	(241,424)	3,219	(324,182)
Balance at end of Period, shares (in Shares) at Dec. 31, 2010	139,640,152
Comprehensive income:
Issuance of common stock for convertible debt	$ 200	112,675			112,875
Issuance of common stock for convertible debt (in Shares)	19,969,069
Issuance of common stock under employee benefit plans, net	$ 1				1
Issuance of common stock under employee benefit plans, net (in Shares)	39,600
Issuance of convertible debt		11,870			11,870
Purchase of purchased call options, net of tax		(13,522)			(13,522)
Proceeds from the sale of warrants		10,868			10,868
Stock-based compensation expense for employees		387			387
Tax benefit from employee stock options		(120)			(120)
Dividends declared		(83,860)			(83,860)
Change in unrealized gains and losses on investments in available-for-sale securities, net of tax				30	30
Change in unrealized gains on cash flow hedges, net of tax				(5,134)	(5,134)
Total comprehensive income					194,285
Net income			199,389		199,389
Balance at end of Period at Dec. 31, 2011	$ 1,397	$ (161,750)	$ (42,035)	$ (1,885)	$ (204,273)
Balance at end of Period, shares (in Shares) at Dec. 31, 2011	139,679,752

Note 1 - Organization and Business

12 Months Ended

Dec. 31, 2011

Business Description and Basis of Presentation [Text Block]

1. Organization and Business

PDL BioPharma Inc. (we, us, our, PDL and the Company) pioneered humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. Today, PDL is focused on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. We receive royalties based on sales of humanized antibody products marketed today and may also receive royalty payments on additional humanized antibody products launched before final patent expiry in December 2014. Under most of our licensing agreements, we are entitled to receive a flat-rate or tiered royalty based upon our licensees’ net sales of covered antibodies. We have also entered into licensing agreements under which we have licensed certain rights for development stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials.

In the year ended December 31, 2011, we received royalties on sales of the seven humanized antibody products listed below, all of which are currently approved for use by the U.S. Food and Drug Administration (FDA) and other regulatory agencies outside the United States. In the years ended December 31, 2011, 2010 and 2009, we received approximately $351.6 million, $343.5 million and $305.0 million, respectively, of royalty revenues under license agreements.

Licensee			Product Names
Genentech, Inc. (Genentech)			Avastin®
			Herceptin®
			Xolair®
			Lucentis®

Elan Corporation, Plc (Elan)			Tysabri®

Wyeth Pharmaceuticals, Inc. (Wyeth)			Mylotarg®

Chugai Pharmaceutical Co., Ltd. (Chugai)			Actemra®

We have also entered into licensing agreements under which we have licensed certain rights under our patents for development-stage products that have not yet reached commercialization including products that are currently in Phase 3 clinical trials.

Until December 2008, our business included biotechnology operations which were focused on the discovery and development of novel antibodies which we spun off (the Spin-Off) to Facet Biotech Corporation (Facet). In April 2010, Abbott Laboratories (Abbott) acquired Facet and later renamed the company Abbott Biotherapeutics Corp.

Note 2 - Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2011

Basis of Presentation and Significant Accounting Policies [Text Block]

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and under the rules and regulations of the Securities and Exchange Commission (SEC).

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, QHP Royalty Sub LLC (QHP). All material intercompany balances and transactions are eliminated in consolidation. We prepare our consolidated financial statements in accordance with the SEC and GAAP and include all adjustments of a normal recurring nature that are necessary to fairly present our consolidated results of operations, financial position and cash flows for all periods presented.

Management Estimates

The preparation of financial statements in conformity with GAAP requires the use of management’s estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Segment Disclosures

We are required to report operating segments and make related disclosures about our products, services, geographic areas and major customers. Our chief operating decision-maker consists of our executive management. Our chief operating decision-maker reviews our operating results and operating plans and makes resource allocation decisions on a company-wide or aggregate basis. As of December 31, 2011, we operated as one segment. Our operations and facilities are located in Incline Village, Nevada.

Cash Equivalents and Investments

We consider all highly liquid investments with initial maturities of three months or less at the date of purchase to be cash equivalents. We place our cash, cash equivalents and investments with high credit quality financial institutions and in U.S. government securities, U.S. government agency securities and investment grade corporate debt securities and, by policy, limit the amount of credit exposure in any one financial instrument. Available-for-sale securities are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). See Note 5.

Fair Value Measurements

The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or we paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;

Level 2 – based on quoted market prices for similar assets and liabilities, using observable market based inputs or unobservable market based inputs corroborated by market data, and

Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable. As of December 31, 2011 and 2010, we had no Level 3 assets or liabilities.

We do not estimate the fair value of our royalty assets for financial statement reporting purposes.

Foreign Currency Hedging

We hedge certain Eurodollar currency exposures related to our licensees’ product sales with Eurodollar forward contracts and Eurodollar option contracts (collectively, Eurodollar contracts). In general, these contracts are intended to offset the underlying Eurodollar market risk in our royalty revenues. Our exposure to credit risk from these contracts is a function of foreign currency exchange rates and, therefore, varies over time. We transact with major banks to limit the credit risk that our counterparty may be unable to perform and monitor the exposure in the context of current market conditions. We mitigate the risk of loss by entering into a netting agreement with our counterparty that provides for aggregate net settlement of all of the Eurodollar contracts should our counterparty default on the contracts prior to contract settlement. Therefore, our overall risk of loss in the event of counterparty default is limited to the net amount of any unrecognized gains or losses on outstanding contracts at the date of default. We do not enter into speculative foreign currency transactions. We have designated the Eurodollar contracts as cash flow hedges. At the inception of the hedging relationship and on a quarterly basis, we assess hedge effectiveness. The aggregate unrealized gain or loss on the effective component of our Eurodollar contracts, net of estimated taxes, is recorded in stockholders’ deficit as accumulated other comprehensive income (loss). Gains or losses on cash flow hedges are recognized as royalty revenue in the same period that the hedged transaction, royalty revenue, impacts earnings.

Revenue Recognition

Royalty Revenues

Under most of our patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

We may also receive minimal annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees are recognized as they are due and when payment is reasonably assured. Total annual milestone payments in each of the last several years have been less than 1% of total revenue.

Comprehensive Income (Loss)

Comprehensive income (loss) comprises net income adjusted for other comprehensive income (loss), which includes the changes in unrealized gains and losses on Eurodollar contracts and changes in unrealized gains and losses on our investments in available-for-sale securities, if any, which are excluded from our net income. The components and accumulated balances of comprehensive income (loss) were:

·	Unrealized gains and losses on cash flow hedges, net of tax, were $(1.9) million at December 31, 2011, $3.2 million at December 31, 2010, and zero at December 31, 2009.

·	Unrealized gains and losses on investments in available-for-sale securities, net of tax, were $29,000 at December 31, 2011, $(1,000) at December 31, 2010, and zero at December 31, 2009.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization were computed using the straight-line method over the following estimated useful lives:

Leasehold improvements	Shorter of asset life or term of lease
Computer and office equipment	3 years
Furniture and fixtures	7 years

Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standards Board (FASB) issued accounting standard update (ASU) 2011-05, eliminating the option to present the components of other comprehensive income as part of the statement of changes in stockholders’ equity. The update requires presentation for items of net income and other comprehensive income either in one continuous statement or in two separate, but consecutive, statements. Additionally, this ASU includes a new requirement to show reclassification adjustments from other comprehensive income to net income on the face of the statement. Except for, the new requirement to show reclassification adjustments from other comprehensive income to income on the face of the income statement, this guidance is required for our first quarter of 2012 with retrospective application also required. We do not expect this guidance to have a material impact on our financial statements.

Note 3 - Net Income per Share

12 Months Ended

Dec. 31, 2011

Earnings Per Share [Text Block]

3. Net Income per Share

We compute net income per basic share using the weighted-average number of shares of common stock outstanding during the period less the weighted-average number of restricted stock shares that are subject to repurchase.

We compute net income per diluted share using the sum of the weighted-average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of net income per diluted share include shares that may be issued under our stock options and restricted stock awards, our 2.00% Convertible Senior Notes due February 15, 2012 (2012 Notes), our 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), and our 2.75% Convertible Subordinated Notes due August 16, 2023 (2023 Notes), on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if-converted method. Our 2023 Notes were fully retired as of September 14, 2010. Our 2012 Notes were fully retired as of June 30, 2011.

The computation for net income per basic and diluted share was:

	Year Ended December 31,
(In thousands)	2011		2010		2009
Numerator
Net income	$	199,389	$	91,874	$	189,660
Add back interest expense for convertible notes, net of estimated tax of $3.0 million, $2.7 million, and $3.8 million for the years ended December 31, 2011, 2010 and 2009, respectively (see Note 12)		5,544		5,087		7,079
Income used to compute net income per diluted share	$	204,933	$	96,961	$	196,739


Denominator
Total weighted-average shares used to compute net income per basic share		139,663		126,578		119,402
Effect of dilutive stock options		13		9		18
Restricted stock outstanding		25		103		42
Assumed conversion of 2012 notes		9,790		29,870		28,809
Assumed conversion of February 2015 notes		27,950		4,229		-
Assumed conversion of 2023 notes		-		18,012		36,129
Shares used to compute net income per diluted share		177,441		178,801		184,400

We excluded 0.2 million, 0.3 million, and 2.5 million of outstanding stock options from our net income per diluted share calculations for the years ended December 31, 2011, 2010 and 2009, respectively, because the option exercise prices were greater than the average market prices of our common stock during these periods; therefore, their effect was anti-dilutive.

In May 2011, we issued 3.75% Senior Convertible Notes due May 1, 2015 (May 2015 Notes). If converted, the principal amount of our May 2015 Notes will be settled in cash and the difference between the conversion value and the principal amounts will be settled in shares of the Company’s common stock. For the year ended December 31, 2011, we excluded a weighted average of 13.3 million shares of potential dilution for our May 2015 Notes and a weighted average of 13.3 million shares of potential dilution for our warrants because the conversion price and exercise price exceeded the average market price of our common stock and were therefore anti-dilutive. These securities could be dilutive in future periods. In addition, we excluded a weighted average of (13.3) million shares for our purchased call options because they will always be anti-dilutive, therefore, will have no effect on diluted net income per share.

For information related to the conversion rates on our convertible debt, see Note 12.

Note 4 - Fair Value Measurements

12 Months Ended

Dec. 31, 2011

Fair Value Disclosures [Text Block]

4. Fair Value Measurements

Assets and liabilities recorded at fair value, by classification category by level of input within the fair value hierarchy defined in Note 2, Summary of Significant Accounting Policies:

	December 31, 2011						December 31, 2010
(In thousands)	Level 1		Level 2		Total		Level 1		Level 2		Total
Assets:
Money market funds	$	163,368	$	-	$	163,368	$	203,318	$	-	$	203,318
Corporate debt securities		-		44,877		44,877		20,434		-		20,434
Commercial paper		-		8,996		8,996		-		7,998		7,998
U.S. government sponsored agency bonds		2,015		-		2,015		8,725		-		8,725
U.S. treasury securities		5,513		-		5,513		1,997		-		1,997
Foreign currency hedge contracts		-		6,838		6,838		-		17,763		17,763
Total	$	170,896	$	60,711	$	231,607	$	234,474	$	25,761	$	260,235

Liabilities:
Foreign currency hedge contracts	$	-	$	9,783	$	9,783	$	-	$	12,810	$	12,810

The fair value of the foreign currency hedging contracts is estimated based on pricing models using readily observable inputs from actively quoted markets and are disclosed on a gross basis.

Corporate debt securities consist primarily of U.S. Corporate bonds. The fair value of corporate debt securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation. No corporate debt securities had been moved from Level 1 inputs to Level 2 inputs at December 31, 2011, as compared to December 31, 2010.

The fair value of commercial paper is estimated based on observable inputs of the comparable securities.

We do not estimate the fair value of our royalty assets for financial statement reporting purposes.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13504-108611

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19296-110258

+ Details

Note 5 - Cash Equivalents, Short-term and Long-term Investments

12 Months Ended

Dec. 31, 2011

Cash, Cash Equivalents, and Marketable Securities [Text Block]

5. Cash Equivalents and Investments

As of December 31, 2011 and 2010, we had invested our excess cash balances primarily in money market funds, corporate debt securities, commercial paper, U.S. government sponsored agency bonds and U.S. treasury securities. Our securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss) in stockholders’ deficit, net of estimated taxes. See Note 4 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, we have not experienced credit losses on investments in these instruments and we do not require collateral for our investment activities.

A summary of our available-for-sale securities at December 31, 2011 and 2010, is presented below:

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
(In thousands)	Cost		Gains		Losses			Value
December 31, 2011:
Money market funds	$	163,368	$	-	$	-		$	163,368
Corporate debt securities		44,863		57		(43	)		44,877
Commercial paper		8,997		-		(1	)		8,996
U.S. government sponsored agency bonds		2,003		12		-			2,015
U.S. treasury securities		5,494		19		-			5,513
Total	$	224,725	$	88	$	(44	)	$	224,769

December 31, 2010:
Money market funds	$	203,318	$	-	$	-		$	203,318
Corporate debt securities		20,437		2		(5	)		20,434
Commercial paper		7,998		-		-			7,998
U.S. government sponsored agency bonds		8,727		-		(2	)		8,725
U.S. treasury securities		1,994		3		-			1,997
Total	$	242,474	$	5	$	(7	)	$	242,472

	December 31,
		2011		2010
Classification on Consolidated Balance Sheets:
Cash equivalents	$	165,367	$	205,817
Short-term investments		42,301		34,658
Long-term investments		17,101		1,997
Total	$	224,769	$	242,472

We did not recognize any gains or losses on sales of available-for-sale securities during 2011, 2010 and 2009.

A summary of our portfolio of available-for-sale debt securities by contractual maturity at December 31, 2011 and 2010, is presented below:

Available-For-Sale Debt Securities by Contractual Maturity	December 31, 2011				December 31, 2010
(In thousands)	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Less than one year	$	44,262	$	44,300	$	37,162	$	37,157
Greater than one year but less than five years		17,095		17,101		1,994		1,997
Total	$	61,357	$	61,401	$	39,156	$	39,154

The unrealized loss on investments included in other comprehensive income (loss), net of estimated taxes, was approximately $29,000 as of December 31, 2011, and $1,000 as of December 31, 2010. No significant facts or circumstances have arisen to indicate that there has been any deterioration in the creditworthiness of the issuers of these securities. Based on our review of these securities, we believe we had no other-than-temporary impairments on these securities as of December 31, 2011, because we do not intend to sell these securities and it is more likely than not that we will hold these securities until the recovery of their amortized cost basis.

Note 6 - Foreign Currency Hedging

12 Months Ended

Dec. 31, 2011

Derivative Instruments and Hedging Activities Disclosure [Text Block]

6. Foreign Currency Hedging

Our licensees operate in foreign countries, which exposes us to market risk associated with foreign currency exchange rate fluctuations between the U.S. dollar and other currencies, primarily the Eurodollar. In order to manage the risk related to changes in foreign currency exchange rates, we entered into a series of Eurodollar contracts covering the quarters in which our licensees’ sales occur through December 2012. Our Eurodollar contracts used to hedge royalty revenues based on underlying Eurodollar sales are designated as cash flow hedges.

The following tables summarize the notional amounts, Eurodollar exchange rates, fair values of our open Eurodollar contracts designated as cash flow hedges and their location on the Consolidated Balance Sheet:

				December 31, 2011					December 31, 2010
Eurodollar Forward Contracts				(in thousands)					(in thousands)

Currency	Settlement Price ($ per Eurodollar)		Type	Notional Amount		Fair Value			Notional Amount		Fair Value
Eurodollar		1.400	Sell Eurodollar	$	25,150	$	1,837		$	137,179	$	6,740
Eurodollar		1.200	Sell Eurodollar		117,941		(9,783	)		117,941		(12,810	)
Total				$	143,091	$	(7,946	)	$	255,120	$	(6,070	)

Eurodollar Option Contracts

Currency	Strike Price ($ per Eurodollar)		Type	Notional Amount		Fair Value		Notional Amount		Fair Value
Eurodollar		1.510	Purchased call option	$	27,126	$	-	$	147,957	$	772
Eurodollar		1.315	Purchased call option		129,244		5,001		129,244		10,251
Total				$	156,370	$	5,001	$	277,201	$	11,023

		Fair Value (In thousands)
Cash Flow Hedge	Location	December 31, 2011		December 31, 2010
Eurodollar contracts, net	Prepaid and other current assets	$	1,837	$	5,946
Eurodollar contracts, net	Accrued liabilities		4,134		-
Eurodollar contracts, net	Other long-term liabilities		648		993

Eurodollar contracts are presented on a net basis on our Consolidated Balance Sheets as we have entered into a netting arrangement with the counterparty. As of December 31, 2011, the unrealized net loss on the effective component of our Eurodollar contracts included in other comprehensive income (loss), net of estimated taxes, was $(1.9) million. As of December 31, 2010, the unrealized net gain on the effective component of our Eurodollar contracts included in other comprehensive income (loss), net of estimated taxes, was $3.2 million. There ineffective component of our foreign currency exchange contracts for the year ended December 31, 2011, was $18,874 and there was no ineffectiveness for the year ended December 30, 2010.

For the years ended December 31, 2011 and 2010, we recognized $1.0 million and $5.2 million in royalty revenues from foreign currency exchange contracts, respectively. Approximately $1.2 million, net of tax, is expected to be reclassified from other comprehensive income (loss) against earnings in the next 12 months. We did not have foreign currency exchange contracts prior to 2010.

- Definition

The entire disclosure for the entity's entire derivative instruments and hedging activities. Describes an entity's risk management strategies, derivatives in hedging activities and non-hedging derivative instruments, the assets, obligations, liabilities, revenues and expenses arising therefrom, and the amounts of and methodologies and assumptions used in determining the amounts of such items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80784-113994

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624181-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624177-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6887037&loc=d3e80748-113994

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624258-113959

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708775-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41635-113959

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5708773-113959

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

+ Details

Note 7 - Prepaid and Other Current Assets

12 Months Ended

Dec. 31, 2011

Prepaid And Other Current Assets [Text Block]

7. Prepaid and Other Current Assets

	December 31,
(In thousands)	2011		2010
Non-recourse Notes issuance costs	$	1,226	$	3,362
Foreign currency exchange		1,837		5,946
Prepaid taxes		8,297		8,307
Other		654		445
Total	$	12,014	$	18,060

For further information about our Non-recourse Notes, see Note 12, Convertible Notes and Non-Recourse Notes.

Note 8 - Property and Equipment

12 Months Ended

Dec. 31, 2011

Property, Plant and Equipment Disclosure [Text Block]

8. Property and Equipment

	December 31,
(In thousands)	2011			2010
Leasehold improvements	$	112		$	112
Computer and office equipment		8,989			8,989
Furniture and fixtures		38			38
Total		9,139			9,139
Less accumulated depreciation and amortization		(9,117	)		(9,059	)
Property and equipment, net	$	22		$	80

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

Note 9 - Other Assets

12 Months Ended

Dec. 31, 2011

Other Assets Disclosure [Text Block]

9. Other Assets

	December 31,
(In thousands)	2011		2010

2012 Notes issuance costs	$	-	$	683
February 2015 Notes issuance costs		3,208		4,226
May 2015 Notes issuance costs		4,134		-
Non-recourse Notes issuance costs		-		2,397
Other		12		-
Total	$	7,354	$	7,306

For further information about our convertible notes and our Non-recourse Notes, see Note 12, Convertible Notes and Non-Recourse Notes.

Note 10 - Accrued Liabilities

12 Months Ended

Dec. 31, 2011

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

10. Accrued Liabilities

	December 31,
(In thousands)	2011		2010

Compensation	$	1,341	$	349
Interest		3,351		2,794
Deferred revenue		1,713		1,713
Foreign currency hedge		4,134		-
Dividend payable		52		20
Other		1,018		2,328
Total	$	11,609	$	7,204

Note 11 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2011

Commitments and Contingencies Disclosure [Text Block]

11. Commitments and Contingencies

Operating Leases

Current Facilities and Equipment

We currently occupy a leased facility in Incline Village, Nevada, with a lease term through May 2012. We also lease certain office equipment under operating leases. Rental expense under these arrangements totaled $0.2 million, $0.1 million and $0.2 million for the years ended December 31, 2011, 2010 and 2009.

As of December 31, 2011, the future minimum operating lease payments were:

(In thousands)
2012	$	176
2013		83
Total	$	259

Contingencies

As permitted under Delaware law, under the terms of our bylaws, we have agreed to indemnify our directors and officers and, under the terms of indemnification agreements we have entered into, we have agreed to indemnify our executive officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was serving as an officer or director of the Company. While the maximum amount of potential future indemnification is unlimited, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid. We believe the fair value of these indemnification agreements and bylaw provisions is minimal and, accordingly, we have not recorded the fair value liability associated with these agreements as of December 31, 2011 and 2010.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

+ Details

Note 12 - Convertible and Non-Recourse Notes

12 Months Ended

Dec. 31, 2011

Long-term Debt [Text Block]

12. Convertible Notes and Non-recourse Notes

Convertible and Non-recourse Notes activity for the year ended December 31, 2011, and fair value at December 31, 2011:

(In thousands)	2012 Notes			February 2015 Notes		May 2015 Notes		Non-recourse Notes			Total
Balance at December 31, 2010	$	133,464		$	176,964	$	-	$	204,270		$	514,698
Issuance		-			-		136,313		-			136,313
Payment		-			-		-		(110,900	)		(110,900	)
Repurchase		(133,464	)		-		-		-			(133,464	)
Discount amortization		-			699		2,639		-			3,338
Balance at December 31, 2011	$	-		$	177,663	$	138,952	$	93,370		$	409,985

Fair value (1)	$	-		$	191,475	$	156,123	$	95,237		$	442,835

(1)	As of December 31, 2011, the fair value of the remaining payments under our convertible notes and Non-recourse Notes was estimated based on the trading value of our notes then outstanding.

May 2015 Notes

On May 16, 2011, we issued $155.3 million in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of $149.7 million. Our May 2015 Notes are due May 1, 2015, and are convertible into 135.9607 shares of the Company’s common stock per $1,000 of principal amount, or approximately $7.36 per share, subject to further adjustment upon certain events including dividend payments. We pay interest at 3.75% on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem our 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to repurchase their May 2015 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

Our May 2015 Notes are convertible under any of the following circumstances:

During any fiscal quarter ending after the quarter ending June 30, 2011, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;

During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;

·	Upon the occurrence of specified corporate events as described further in the indenture; or

·	At any time on or after November 1, 2014.

If a conversion occurs, to the extent that the conversion value exceeds the principal amount, the principal amount is due in cash and the difference between the conversion value and the principal amount is due in shares of the Company’s common stock. As of December 31, 2011, the if-converted amount of our May 2015 Notes was less than the principal amount.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our May 2015 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.5%, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of $18.9 million, allocated $12.3 million to additional paid-in capital and $6.6 million to deferred tax liability. The discount is being amortized to interest expense over the term of our May 2015 Notes and increases interest expense during the term of our May 2015 Notes from the 3.75% cash coupon interest rate to an effective interest rate of 7.5%. As of December 31, 2011, the remaining discount amortization period is 3.3 years.

The carrying value and unamortized discount of our May 2015 Notes were:

(In thousands)	December 31, 2011
Principal amount of the May 2015 Notes	$	155,250
Unamortized discount of liability component		(16,298	)
Net carrying value of the May 2015 Notes	$	138,952

Interest expense for our May 2015 Notes on the Consolidated Statements of Income was:

	For the Period May 16 to
(In thousands)	December 31, 2011
Contractual coupon interest	$	3,639
Amortization of debt issuance costs		727
Amortization of debt discount		2,639
Total	$	7,005

In connection with the issuance of our May 2015 Notes, we entered into purchased call option transactions with two hedge counterparties entitling the Company to initially purchase up to 19.6 million shares of the Company’s common stock. In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for up to 27.5 million shares of the Company’s common stock. The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our May 2015 Notes. The strike prices are approximately $7.36 and $8.65, subject to further adjustment upon certain events including dividend payments, for the purchased call options and warrants, respectively.

If the share price is above $7.36, upon conversion of our May 2015 Notes, the purchased call options will offset the share dilution, because the Company will receive shares on exercise of the purchased call options equal to the shares that the Company must deliver to the note holders. If the share price is above $8.65, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $8.65. For example, a 10% increase in the share price above $8.65 would result in the issuance of 1.9 million incremental shares upon exercise of the warrants. As our share price continues to increase, additional dilution would occur.

While the purchased call options are expected to reduce the potential equity dilution upon conversion of our May 2015 Notes, prior to conversion or exercise, our May 2015 Notes and the warrants could have a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock during a given measurement period exceeds the respective exercise prices of those instruments. As of December 31, 2011, the market price condition for convertibility of our May 2015 Notes was not met and there were no related purchased call options or warrants exercised.

The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at December 31, 2011. The purchased call options cost, including legal fees, of $20.8 million, less deferred taxes of $7.2 million, and the $10.9 million received for the warrants were recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet the criteria for equity classification.

Purchased Call Options

We paid an aggregate amount of $20.8 million to two hedge counterparties, plus legal fees, for the purchased call options with terms substantially similar to the embedded conversion options in our May 2015 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our May 2015 Notes, approximately 21.1 million shares of our common stock at a strike price of approximately $7.36, which corresponds to the conversion price of our May 2015 Notes. We may exercise the purchased call options upon conversion of our May 2015 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on May 1, 2015, or the last day any of our May 2015 Notes remain outstanding.

Warrants

We received an aggregate amount of $10.9 million from the two hedge counterparties for the sale of rights to receive up to 27.5 million shares of common stock underlying our May 2015 Notes, at a current strike price of approximately $8.65 per share, subject to additional anti-dilution and certain other customary adjustments. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time ending on January 20, 2016. If the volume weighted average share price of our common stock, as defined in the warrants (VWAP), exceeds the strike price of the warrants, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

February 2015 Notes

On November 1, 2010, we completed an exchange of $92.0 million in aggregate principal of our 2012 Notes in separate, privately negotiated transactions with the note holders. In the exchange transactions, the note holders received $92.0 million in aggregate principal of our February 2015 Notes, and we recorded a net gain of $1.1 million. As part of the transaction, we placed an additional $88.0 million in aggregate principal of our February 2015 Notes. Our February 2015 Notes are due February 15, 2015, and are convertible at any time, at the holders’ option, into our common stock at a conversion price of 155.396 shares of common stock per $1,000 principal amount, or $6.44 per share, subject to further adjustment in certain events including dividend payments. We pay interest on our February 2015 Notes semiannually in arrears on February 15 and August 15 of each year. Our February 2015 Notes are senior unsecured debt and are redeemable by us in whole or in part on or after August 15, 2014, at 100% of principal amount. Our February 2015 Notes are not puttable by the note holders other than in the context of a fundamental change resulting in the reclassification, conversion, exchange or cancellation of our common stock. Such repurchase event or fundamental change is generally defined to include a merger involving PDL, an acquisition of a majority of PDL’s outstanding common stock and a change of a majority of PDL’s board of directors without the approval of the board of directors. Our February 2015 Notes issuance was not registered under the Securities Act of 1933, as amended, in reliance on exemption from registration thereunder. As of December 31, 2011, our February 2015 Notes aggregate principal outstanding was $180.0 million.

As of December 31, 2011, our February 2015 Notes unamortized issuance costs, included as a component of Other assets on the Consolidated Balance Sheets, were $3.2 million. As of December 31, 2011, the unamortized discount on our February 2015 Notes was $2.3 million. The issuance cost and discount are being amortized to interest expense over the term of our February 2015 Notes, with a remaining amortization period of approximately 3.2 years.

In January and February 2012, we completed exchange transactions where we exchanged our February 2015 Notes for our new 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes). For further information regarding the Series 2012 Notes, see Note 19.

2012 Notes Retirement

Our 2012 Notes of $133.5 million aggregate principal were fully retired at June 30, 2011, at a redemption price of 100.29% of principal for aggregate consideration of $133.9 million plus interest of $1.0 million. We recorded a net loss of $0.8 million from the redemption of the debt.

In 2010, we exchanged $92.0 million in aggregate principal of our 2012 Notes for February 2015 Notes. In addition, we repurchased $2.5 million aggregate principal value of our 2012 Notes at a discount of 0.5% to face value in an open market transaction for aggregate consideration of $2.5 million in cash, plus accrued interest. Also in 2010, certain holders of the 2012 Notes converted an aggregate of $10,000 principal of our 2010 Notes into 1,283 shares of common stock.

In 2009, the Company repurchased $22.0 million aggregate principal of our 2012 Notes, for aggregate consideration of $21.0 million in cash, plus accrued interest. We recorded a net gain of $0.8 million from the redemption of the debt.

2023 Notes Retirement

As of December 31, 2010, our 2023 Notes were fully retired. In 2010, $111.7 million aggregate principal of our 2023 Notes were converted into 20.0 million shares of common stock, and we recorded a $2.4 million loss on the induced conversion to shares of common stock. Additionally, $88.4 million aggregate principal of our 2023 Notes were redeemed for $104.6 million. In 2009, we repurchased $50.0 million aggregate principal of our 2023 Notes, for aggregate consideration of $49.0 million in cash, plus accrued interest and recorded a net gain of $0.7 million.

Non-recourse Notes

In November 2009, we completed a $300 million securitization transaction in which we monetized 60% of the net present value of the estimated five year royalties from sales of Genentech products (the Genentech Royalties) including Avastin®, Herceptin®, Lucentis®, Xolair® and future products, if any, under which Genentech may take a license under our related agreements with Genentech. Our QHP PhaRMASM Senior Secured Notes due 2015 (Non-recourse Notes) bear interest at 10.25% per annum and were issued in a non-registered offering by QHP, a Delaware limited liability company, and a newly formed, wholly-owned subsidiary of PDL. Concurrent with the securitization transaction and under the terms of a purchase and sale agreement, we sold, transferred, conveyed, assigned, contributed and granted to QHP, certain rights under our non-exclusive license agreements with Genentech including the right to receive the Genentech Royalties in exchange for QHP’s proceeds from our Non-recourse Notes issuance. Once all obligations on our Non-recourse Notes have been paid in full, including all other sums payable under the indenture, the indenture shall cease to be of further effect and all of the security interests in the collateral shall terminate, including the pledge by PDL to the trustee of its equity interest in QHP. At such point, there will be no further restrictions on the Genentech Royalties and PDL shall be free to either keep them in QHP, transfer them back to PDL or to further dispose or monetize them.

The Genentech Royalties and other payments, if any, that QHP will be entitled to receive under the agreements with Genentech, together with any funds made available from certain accounts of QHP, will be the sole source of payment of principal and interest on our Non-recourse Notes, which will be secured by a continuing security interest granted by QHP in its rights to receive payments under such agreements and all of its other assets and a pledge by PDL of its equity ownership interest in QHP. Our Non-recourse Notes may be redeemed at any time prior to maturity, in whole or in part, at the option of QHP at a make-whole redemption price. As of December 31, 2011, the remaining principal balance was $93.4 million,

As of December 31, 2011, the remaining unamortized issuance costs were $1.2 million, and are included as a component of Prepaid and other current assets on the Consolidated Balance Sheets. These costs are being amortized to interest expense using the effective interest method over the estimated repayment period, or approximately three years.

As of December 31, 2011, PDL was in compliance with all applicable debt covenants, and embedded features of all debt agreements were evaluated and did not need to be accounted for separately.

As of December 31, 2011, the future minimum principal payments under our February 2015 Notes, our May 2015 Notes and our Non-recourse Notes were:

	February		May
	2015		2015		Non-recourse
(In thousands)	Notes		Notes		Notes (1)		Total
2012	$	-	$	-	$	93,370	$	93,370
2013		-		-		-		-
2014		-		-		-		-
2015		180,000		155,250		-		335,250
Total	$	180,000	$	155,250	$	93,370	$	428,620

(1)	Repayment of our Non-recourse Notes is based on anticipated future royalties to be received from Genentech and the anticipated final payment date is September 2012.

Note 13 - Other Long-Term Liabilities

12 Months Ended

Dec. 31, 2011

Other Liabilities Disclosure [Text Block]

13. Other Long-Term Liabilities

	December 31,
(In thousands)	2011		2010
Accrued lease liability	$	10,700	$	10,700
Accrued legal settlement		-		27,500
Uncertain tax position		12,774		12,213
Foreign currency hedge		648		993
Total	$	24,122	$	51,406

In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant under the leases, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we would be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of December 31, 2011, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $110.8 million. We would also be responsible for lease-related costs including utilities, property taxes and common area maintenance which may be as much as the actual lease payments if Facet were to default. In April 2010, Abbott acquired Facet and later renamed the company Abbott Biotherapeutics Corp.

As of December 31, 2011 and 2010, we had a liability of $10.7 million on our Consolidated Balance Sheets for the estimated fair value of this guarantee. In future periods, we may increase the recorded liability for this obligation if we conclude that a loss, which is larger than the amount recorded, is both probable and estimable.

Note 14 - Stock-Based Compensation

12 Months Ended

Dec. 31, 2011

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

14. Stock-Based Compensation

We recognize compensation expense, using a fair-value based method, for costs associated with all share-based awards issued to our directors, employees and outside consultants under our stock plan. The value of the portion of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service periods in our Consolidated Statements of Income.

We have adopted the simplified method to calculate the beginning balance of the additional paid-in capital (APIC) pool of the excess tax benefit and to determine the subsequent effect on the APIC pool and Consolidated Statements of Cash Flows of the tax effects of employee stock-based compensation awards that were outstanding upon our adoption.

We calculate stock-based compensation expense based on the number of awards ultimately expected to vest, net of estimated forfeitures. We estimate forfeiture rates at the time of grant and revise such rates, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The stock-based compensation expense was determined using the Black-Scholes option valuation model.

Stock-based compensation expense for directors and employees for the years ended December 31, 2011, 2010 and 2009, was $337,000, $662,000 and $773,000, respectively.

The stock-based compensation expense related to non-employees for the years ended December 31, 2011, 2010 and 2009, was $50,000, zero, and $48,000, respectively.

Stock-Based Incentive Plans

We currently have one active stock-based incentive plan under which we may grant stock-based awards to our employees, directors and consultants.

The total number of shares of common stock authorized for issuance, shares of common stock issued upon exercise of options or grant of restricted stock, shares of common stock subject to outstanding awards and available for grant under this plan as of December 31, 2011, is:

					Total Shares of		Total Shares of
	Total Shares of		Total Shares of		Common Stock		Common Stock
	Common Stock		Common Stock		Subject to		Available for
Title of Plan	Authorized		Issued		Outstanding Awards		Grant
2005 Equity Incentive Plan(1)		5,200,000		490,143		-		4,709,857
2002 Outside Directors Stock Option Plan(2)		157,000		140,750		16,250		-
1999 Non-statutory Stock Option Plan(2)		5,075,707		4,966,183		109,524		-
1999 Stock Option Plan(2)		3,758,719		3,653,150		105,569		-

(1)	As of December 31, 2011, there were 136,507 shares of unvested restricted stock awards outstanding.

(2)	Plan terminated in 2009, subject to options outstanding under the plan.

Under our 2005 Equity Incentive Plan, we are authorized to issue a variety of incentive awards, including stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance share and performance unit awards, deferred compensation awards and other stock-based or cash-based awards.

In 2009, our Compensation Committee terminated the 1991 Nonstatutory Stock Option Plan. Additionally our Compensation Committee terminated the 1999 Outside Director Stock Option Plan, the 1999 Nonstatutory Stock Option Plan and the 2002 Outside Directors Stock Option Plan, subject to any outstanding options. Also in June 2009, our stockholders approved amendments to the Company’s 2005 Equity Incentive Plan to expand persons eligible to participate in the plan to include our outside directors.

Stock Option Activity

A summary of our stock option activity is presented below:

	2011					2010					2009

				Weighted-					Weighted-					Weighted-
	Number of			Average		Number of			Average		Number of			Average
	shares			Exercise		shares			Exercise		shares			Exercise
	(in thousands)			Price		(in thousands)			Price		(in thousands)			Price
Outstanding at beginning of year		274		$	17.25		1,564		$	19.82		5,776		$	18.04
Exercised		-			-		-			-		(213	)		6.57
Forfeited		(43	)		20.67		(1,290	)		20.36		(3,999	)		17.96
Outstanding at end of year		231			16.62		274			17.25		1,564			19.82
Exercisable at end of year		231			16.62		274			17.25		1,543			20.01

As of December 31, 2011, the aggregate intrinsic value of our outstanding and exercisable stock options was $45,000 and the weighted-average remaining contractual life was 2.33 years. The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the closing prices of our common stock of $6.20 on December 31, 2011, which would have been received by the option holders had option holders exercised their options as of that date. In connection with the Spin-Off of Facet in December 2008, we terminated substantially all employees. As a result, approximately 4 million options with an average exercise price of $17.96 were forfeited during the year ended December 31, 2009. All stock options were fully vested in 2010.

Additional information regarding our options exercised is set forth below:

	Year Ended December 31,
(In thousands)	2011		2010		2009
Cash received	$	-	$	-	$	1,402
Aggregate intrinsic value	$	-	$	-	$	326

Restricted Stock

Restricted stock has the same rights as other issued and outstanding shares of the Company’s common stock including, in some cases, the right to accrue dividends, and are held in escrow until the award vests. The compensation expense related to these awards is determined using the fair market value of the Company’s common stock on the date of the grant, and the compensation expense is recognized over the vesting period. Restricted stock awards typically vest over twelve to twenty-four months. In addition to service requirements, vesting of restricted stock awards, may be subject to the achievement of specified performance goals set by the Compensation Committee of the Company’s Board of Directors. If the performance goals are not met, no compensation expense is recognized and any previously recognized compensation expense is reversed.

A summary of our restricted stock activity is presented below:

	2011					2010					2009
	Number of shares (in thousands)			Weighted- average grant-date fair value per share		Number of shares (in thousands)			Weighted- average grant-date fair value per share		Number of shares (in thousands)			Weighted- average grant-date fair value per share
Nonvested at beginning of year		40		$	5.05		148		$	6.54		-		$	-
Awards granted		155			6.15		40			5.05		159			6.54
Awards vested		(40	)		5.05		(148	)		6.54		(5	)		6.43
Forfeited		(18	)		6.59		-			-		(6	)		6.66
Nonvested at end of year		137			6.09		40			5.05		148			6.54

Stock-based compensation expense associated with our restricted stock for the years ended December 31, 2011, 2010 and 2009, was $0.4 million, $0.6 million and $0.5 million, respectively. As of December 31, 2011, the aggregate intrinsic value of non-vested restricted stock was $0.8 million. Total unrecognized compensation costs associated with non-vested restricted stock as of December 31, 2011, was $0.5 million, excluding forfeitures, which we expect to recognize over a weighted-average period of ten months.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

+ Details

Note 15 - Cash Dividends

12 Months Ended

Dec. 31, 2011

Stockholders' Equity Note Disclosure [Text Block]

15. Cash Dividends

On January 18, 2012, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in 2012 will be $0.15 per share of common stock, payable on March 14, June 14, September 14 and December 14 of 2012 to stockholders of record on March 7, June 7, September 7 and December 7 of 2012, the record dates for each of the dividend payments, respectively.

On February 25, 2011, our board of directors declared regular quarterly dividends of $0.15 per share of common stock, which were paid on March 15, June 15, September 15 and December 15 of 2011 to stockholders of record on March 8, June 8, September 8 and December 8 of 2011, the record dates for each of the dividend payment dates, respectively. We paid $83.8 million in dividends in 2011.

In January 2010, our board of directors declared two special cash dividends of $0.50 per share of common stock payable on April 1, 2010, and October 1, 2010. We paid $59.9 million to our stockholders on April 1, 2010, and $69.8 million to our stockholders on October 1, 2010. As of December 31, 2010, we had $20,000 accrued in other accrued liabilities for estimated dividends payable on unvested restricted stock.

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 4
-Section 08
-Paragraph d

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 1
-Section B
-Paragraph 7, 11A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

+ Details

Note 16 - Customer Concentration

12 Months Ended

Dec. 31, 2011

Concentration Risk Disclosure [Text Block]

16. Customer Concentration

The percentage of total revenue earned from licensees net sales, which individually accounted for 10% or more of our total revenues:

	Year Ended December 31,
	2011			2010			2009
Licensees
Genentech, Inc. (Genentech)		86	%		86	%		71	%
Elan Corporation, Plc (Elan)		12	%		10	%		9	%
MedImmune, Inc. (MedImmune)		0	%		0	%		13	%

Total revenues by geographic area are based on the country of domicile of the counterparty to the agreement:

	Year Ended December 31,
(In thousands)	2011		2010		2009
United States	$	137,269	$	130,070	$	154,706
Europe		224,472		213,677		160,743
Other		300		1,228		2,735
Total revenues	$	362,041	$	344,975	$	318,184

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 21, 22, 24
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6327-108592

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13531-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6442-108592

+ Details

Note 17 - Income Taxes

12 Months Ended

Dec. 31, 2011

Income Tax Disclosure [Text Block]

17. Income Taxes

The provision for income taxes for the years ended December 31, 2011, 2010 and 2009, consisted of the following:

	Year Ended December 31.
(In thousands)	2011		2010			2009
Current income tax expense
Federal	$	83,569	$	91,325		$	87,402
State		1		11			(573	)
Total current		83,570		91,336			86,829

Deferred income tax (benefit)		24,469		(32,840	)		3,796
Total provision	$	108,039	$	58,496		$	90,625

A reconciliation of the income tax provision computed using the U.S. statutory federal income tax rate compared to the income tax provision for income included in the Consolidated Statements of Income is:

	Year Ended December 31,
(In thousands)	2011		2010		2009
Tax at U.S. statutory rate on income before income taxes	$	107,600	$	52,630	$	98,100
Change in valuation allowance		-		296		4,891
State taxes		1		11		(573	)
Net operating loss re-establishment		-		-		(9,174	)
Non-deductible loss on retirement or conversion of convertible notes		-		4,960		-
Other		438		599		(2,619	)
Total	$	108,039	$	58,496	$	90,625

Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets and liabilities, as well as net operating loss carryforwards and are measured using the enacted tax rates and laws in effect when the differences are expected to reverse. The significant components of our net deferred tax assets and liabilities are:

	December 31,
(In thousands)	2011			2010
Deferred tax assets:
Net operating loss carryforwards	$	7,308		$	7,930
Research and other tax credits		5,743			5,743
Intangible assets		7,403			8,952
Stock-based compensation		273			339
Reserves and accruals		10,087			32,541
Deferred revenue		600			599
Unrealized loss on foreign currency hedge contracts		1,031			-
Other		974			506
Total deferred tax assets		33,419			56,610
Valuation allowance		(10,930	)		(10,930	)
Total deferred tax assets, net of valuation allowances		22,489			45,680
Deferred tax liabilities:
Deferred gain on repurchase of convertible notes		(954	)		(1,079	)
Unrealized gain on foreign currency hedge contracts		-			(2,079	)
Total deferred tax liabilities		(954	)		(3,158	)
Net deferred tax assets	$	21,535		$	42,522

As of December 31, 2011 and 2010, we had federal net operating loss carryforwards of $42.9 million and $44.7 million, respectively. The federal net operating loss carryforwards will expire in the year 2023, if not used. In addition, as we moved our entire operations outside of California in 2008, it is unlikely that we will realize any future benefit from any state net operating loss and credit carryforwards. The net operating loss carryforwards which resulted from exercises of stock options were not recorded on the Consolidated Balance Sheet. Instead, such unrecognized deferred tax benefits were accounted for as a credit to additional paid-in capital and were realized through a reduction in taxes payable.

Use of the federal net operating loss and tax credit carryforwards may be subject to a substantial annual limitation due to the “change in ownership” provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before they are used. We have an annual limitation on the use of our federal operating losses of $1.8 million for each of the years ended December 31, 2012 to 2022, and $1.3 million for the year ended December 31, 2023. As of December 31, 2011, we estimate that at least $22.0 million of the $42.9 million of federal net operating loss carryforwards will expire prior to their use due to change of ownership provisions.

During the year ended December 31, 2011, we recorded no change in our liability associated with uncertain tax positions. A reconciliation of our unrecognized tax benefits, excluding accrued interest and penalties, for 2011 and 2010 is:

	December 31,
(In thousands)	2011		2010
Balance at the beginning of the year	$	23,061	$	23,116
Expiration of statute of limitations for the assessment of taxes		-		(55	)
Balance at the end of the year	$	23,061	$	23,061

The future impact of the unrecognized tax benefit of $23.1 million, if recognized, is as follows: $12.2 million would affect the effective tax rate and $10.9 million would result in adjustments to deferred tax assets and corresponding adjustments to the valuation allowance.

Estimated interest and penalties associated with unrecognized tax benefits increased income tax expense in the Consolidated Statements of Income by $0.5 million during the year ended December 31, 2011, and decreased income tax expense by $26,000 and $0.4 million during the years ended December 31, 2010 and 2009, respectively. In general, our income tax returns are subject to examination by U.S. federal, state, and local tax authorities for tax years 1995 forward. The IRS is currently examining our 2008 tax return. We are also currently under income tax examination in the state of California for tax years 2008 and 2009.

Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefits over the next 12 months.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 136, 172
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43, 44, 45, 46, 47, 48, 49
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

+ Details

Note 18 - Legal Proceedings

12 Months Ended

Dec. 31, 2011

Legal Matters and Contingencies [Text Block]

18. Legal Proceedings

Resolution of Challenges against the Queen et al. Patents in the United States and Europe

MedImmune Settlement

On February 10, 2011, we entered into a definitive settlement agreement with MedImmune, LLC (MedImmune) resolving all legal disputes with them, including those relating to MedImmune’s product Synagis® and PDL’s patents known as the Queen et al. patents. Under the settlement agreement, PDL paid MedImmune $65.0 million on February 15, 2011, and an additional $27.5 million on February 9, 2012, for a total of $92.5 million. No further payments will be owed by MedImmune to PDL under its license to the Queen et al. patents as a result of past or future Synagis sales and MedImmune will cease any support, financial or otherwise, of any party involved in the appeal proceeding before the European Patent Office (EPO) relating to the opposition against European Patent No. 0 451 216B (the ‘216B Patent) including the opposition owned by BioTransplant Incorporated (BioTransplant).

Settlement with UCB

On February 2, 2011, we reached a settlement with UCB Pharma S.A. (UCB). Under the settlement agreement, PDL provided UCB a covenant not to sue UCB for any royalties regarding UCB’s Cimzia® product under the Queen et al. patents in return for a lump sum payment of $10 million to PDL and termination of pending patent interference proceedings before the U.S. Patent and Trademark office (PTO) involving our U.S. Patent No. 5,585,089 patent (the ‘089 Patent) and our U.S. Patent No. 6.180.370 (the ‘370 Patent) in PDL’s favor. UCB also agreed to formally withdraw its opposition appeal challenging the validity of the ‘216B Patent.

Settlement with Novartis

On February 25, 2011, we reached a settlement with Novartis AG (Novartis). Under the settlement agreement, PDL agreed to dismiss its claims against Novartis in its action in Nevada state court which also includes Genentech, Inc. (Genentech) and F. Hoffman Roche Ltd (Roche) as defendants. Novartis agreed to withdraw its opposition appeal in the EPO challenging the validity of the ‘216B Patent. Under the settlement agreement with Novartis, we will pay Novartis certain amounts based on net sales of Lucentis made by Novartis during calendar year 2011 and beyond. The settlement does not affect our claims against Genentech and Roche in the Nevada state court action. We do not currently expect such amount to materially impact our total annual revenues.

European Opposition to ‘216B Patent

Termination of European Opposition to ‘216B Patent

Pursuant to our settlements with UCB, MedImmune and Novartis, and as a result of our acquisition of BioTransplant and subsequent withdrawal of BioTransplant’s appeal, all of the active appellants in the EPO opposition have formally withdrawn their participation in the appeal proceeding. Accordingly, the EPO has cancelled the appeal proceeding and terminated the opposition proceeding in its entirety, with the result that the 2007 EPO decision upholding the claims of our ‘216B Patent as valid will become the final decision of the EPO. In the year ending December 31, 2011, approximately 33% of our royalty revenues were derived from sales of products that were made in Europe and sold outside of the United States.

Genentech / Roche Matter

Communications with Genentech regarding European SPCs

In August 2010, we received a letter from Genentech, sent on behalf of Roche and Novartis, asserting that Avastin, Herceptin, Lucentis and Xolair (the Genentech Products) do not infringe the supplementary protection certificates (SPCs) granted to PDL by various countries in Europe for each of the Genentech Products and seeking a response from PDL to these assertions. Genentech did not state what actions, if any, it intends to take with respect to its assertions. PDL’s SPCs were granted by the relevant national patent offices in Europe and specifically cover the Genentech Products. The SPCs covering the Genentech Products effectively extend our European patent protection for the ‘216B Patent generally until December 2014, except that the SPCs for Herceptin will generally expire in July 2014.

Genentech’s letter does not suggest that the Genentech Products do not infringe PDL’s U.S. patents to the extent that such Genentech Products are made, used or sold in the United States (U.S.-based Sales). Genentech’s quarterly royalty payments received in August and November of 2010 after receipt of the letter included royalties generated on all worldwide sales of the Genentech Products.

If Genentech is successful in asserting this position, then under the terms of our license agreements with Genentech, it would not owe us royalties on sales of the Genentech Products that are both manufactured and sold outside of the United States. Royalties on sale of the Genentech Products that are made and sold outside of the United States (ex-U.S.-based Manufacturing and Sales) accounted for approximately 33% of our royalty revenues for the year ended December 31, 2011. Based on announcements by Roche regarding moving more manufacturing outside of the United States, we expect this amount to increase in the future.

We believe that the SPCs are enforceable against the Genentech Products, that Genentech’s letter violates the terms of the 2003 settlement agreement and that Genentech owes us royalties on sales of the Genentech Products on a worldwide basis. We intend to vigorously assert our SPC-based patent rights.

Nevada Litigation with Genentech, Roche and Novartis in Nevada State Court

In August 2010, we filed a complaint in the Second Judicial District of Nevada, Washoe County, naming Genentech, Roche and Novartis as defendants. We intend to enforce our rights under our 2003 settlement agreement with Genentech and are seeking an order from the court declaring that Genentech is obligated to pay royalties to us on ex-U.S.-based Manufacturing and Sales of the Genentech Products.

The 2003 settlement agreement was entered into as part of a definitive agreement resolving intellectual property disputes between the two companies at that time. The agreement limits Genentech’s ability to challenge infringement of our patent rights and waives Genentech’s right to challenge the validity of our patent rights. Certain breaches of the 2003 settlement agreement as alleged by our complaint require Genentech to pay us liquidated and other damages of potentially greater than one billion dollars. This amount includes a retroactive royalty rate of 3.75% on past U.S.-based Sales of the Genentech Products and interest, among other items. We may also be entitled to either terminate our license agreements with Genentech or be paid a flat royalty of 3.75% on future U.S.-based Sales of the Genentech Products.

In November 2010, Genentech and Roche filed a motion to dismiss our complaint against them in which we seek to enforce our rights under the 2003 settlement agreement with Genentech. Genentech and Roche's motions to dismiss under Nevada Rule of Civil Procedure 12(b)(5) alleged that all of our claims for relief relating to the 2003 settlement agreement should be dismissed because the 2003 settlement agreement applies only to our U.S. patents. In addition, Roche filed a separate motion to dismiss our complaint under Nevada Rule of Civil Procedure 12(b)(2) on the ground that the Nevada court lacks personal jurisdiction over Roche. On July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of us on the two motions to dismiss filed by Genentech and Roche. The court denied Genentech and Roche's motion to dismiss four of our five claims for relief and, further, denied Roche's separate motion to dismiss for lack of personal jurisdiction. The court dismissed one of our claims that Genentech committed a bad-faith breach of the covenant of good faith and fair dealing stating that, based on the current state of the pleadings, no "special relationship" had been established between Genentech and us as required under Nevada law. On November 1, 2011, the Nevada court issued an order accepting Roche’s stipulation of waiver to its personal jurisdiction defense. As a result of the order, Roche is foreclosed from reliance on lack of personal jurisdiction in defending against our claims.

On February 25, 2011, we reached a settlement with Novartis under which, among other things, we agreed to dismiss our claims against Novartis in the action in Nevada state court against Genentech, Roche and Novartis. Genentech and Roche continue to be parties to the Nevada suit.

Note 19 - Subsequent Event

12 Months Ended

Dec. 31, 2011

Subsequent Events [Text Block]

19. Subsequent Event

In January 2012, we completed an exchange transaction where we exchanged and subsequently retired approximately $169.0 million aggregate principal amount, representing approximately 93.9%, of our 2.875% Convertible Senior Notes due February 15, 2015 (February 2015 Notes), for approximately $169.0 million aggregate principal amount of new 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes), plus a cash payment of $5.00 for each $1,000 principal amount tendered for a total cash incentive payment of approximately $0.8 million. In February 2012, we entered into separate privately negotiated exchange agreements under which we retired an additional $10.0 million aggregate principal amount of our February 2015 Notes for $10.0 million aggregate principal amount of our Series 2012 Notes. Following settlement of the exchanges on February 2, 2012, $1.0 million of our February 2015 Notes and $179.0 million of our Series 2012 Notes were outstanding. Like our May 2015 Notes, our Series 2012 Notes net share settle. The effect of issuing $179.0 million aggregate principal of our Series 2012 Notes with the net share settle feature in exchange for our February 2015 Notes was the reduction of 27.8 million shares of potential dilution to our stockholders.

Our Series 2012 Notes bear interest at a rate of 2.875% per annum, payable semiannually in arrears on February 15 and August 15 of each year, beginning on February 15, 2012. The conversion rate for our new Series 2012 Notes is 155.396 shares of the Company’s common stock per $1,000 principal amount, which is equivalent to an initial conversion price of approximately $6.44 per share of common stock.

Note 20 - Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2011

Quarterly Financial Information [Text Block]

20. Quarterly Financial Data (Unaudited)

	2011 Quarter Ended
(In thousands, except per share data)	December 31		September 30		June 30		March 31
Revenues	$	72,808	$	83,770	$	122,127	$	83,336
Net income	$	38,942	$	45,916	$	69,986	$	44,545
Net income per basic share	$	0.28	$	0.33	$	0.50	$	0.32
Net income per diluted share	$	0.24	$	0.28	$	0.38	$	0.25

	2010 Quarter Ended
(In thousands, except per share data)	December 31			September 30		June 30		March 31
Revenues	$	76,129		$	86,442	$	120,343	$	62,061
Net income	$	(24,460	)	$	40,189	$	50,138	$	26,007
Net income per basic share	$	(0.18	)	$	0.32	$	0.42	$	0.22
Net income per diluted share	$	(0.18	)	$	0.24	$	0.30	$	0.15

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2011
Basis of Accounting [Text Block]	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and under the rules and regulations of the Securities and Exchange Commission (SEC).
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, QHP Royalty Sub LLC (QHP). All material intercompany balances and transactions are eliminated in consolidation. We prepare our consolidated financial statements in accordance with the SEC and GAAP and include all adjustments of a normal recurring nature that are necessary to fairly present our consolidated results of operations, financial position and cash flows for all periods presented.
Use of Estimates, Policy [Policy Text Block]	Management Estimates The preparation of financial statements in conformity with GAAP requires the use of management's estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Segment Reporting, Policy [Policy Text Block]	Segment Disclosures We are required to report operating segments and make related disclosures about our products, services, geographic areas and major customers. Our chief operating decision-maker consists of our executive management. Our chief operating decision-maker reviews our operating results and operating plans and makes resource allocation decisions on a company-wide or aggregate basis. As of December31, 2011, we operated as one segment. Our operations and facilities are located in Incline Village, Nevada.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents and Investments We consider all highly liquid investments with initial maturities of three months or less at the date of purchase to be cash equivalents. We place our cash, cash equivalents and investments with high credit quality financial institutions and in U.S. government securities, U.S.government agency securities and investment grade corporate debt securities and, by policy, limit the amount of credit exposure in any one financial instrument. Available-for-sale securities are reported at fair value, with unrealized gains and losses recorded in accumulated other comprehensive income (loss). See Note 5.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value Measurements The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or we paid to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one the following three categories: Level 1 - based on quoted market prices in active markets for identical assets and liabilities; Level 2 - based on quoted market prices for similar assets and liabilities, using observable market based inputs or unobservable market based inputs corroborated by market data, and Level 3 - based on unobservable inputs using management's best estimate and assumptions when inputs are unavailable. As of December 31, 2011 and 2010, we had no Level 3 assets or liabilities. We do not estimate the fair value of our royalty assets for financial statement reporting purposes.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Hedging We hedge certain Eurodollar currency exposures related to our licensees' product sales with Eurodollar forward contracts and Eurodollar option contracts (collectively, Eurodollar contracts). In general, these contracts are intended to offset the underlying Eurodollar market risk in our royalty revenues. Our exposure to credit risk from these contracts is a function of foreign currency exchange rates and, therefore, varies over time. We transact with major banks to limit the credit risk that our counterparty may be unable to perform and monitor the exposure in the context of current market conditions. We mitigate the risk of loss by entering into a netting agreement with our counterparty that provides for aggregate net settlement of all of the Eurodollar contracts should our counterparty default on the contracts prior to contract settlement. Therefore, our overall risk of loss in the event of counterparty default is limited to the net amount of any unrecognized gains or losses on outstanding contracts at the date of default. We do not enter into speculative foreign currency transactions. We have designated the Eurodollar contracts as cash flow hedges. At the inception of the hedging relationship and on a quarterly basis, we assess hedge effectiveness. The aggregate unrealized gain or loss on the effective component of our Eurodollar contracts, net of estimated taxes, is recorded in stockholders' deficit as accumulated other comprehensive income (loss). Gains or losses on cash flow hedges are recognized as royalty revenue in the same period that the hedged transaction, royalty revenue, impacts earnings.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Royalty Revenues Under most of our patent license agreements, we receive royalty payments based upon our licensees' net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees. We may also receive minimal annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees are recognized as they are due and when payment is reasonably assured. Total annual milestone payments in each of the last several years have been less than 1% of total revenue.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization were computed using the straight-line method over the following estimated useful lives:

- Definition

Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 1
-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 7, 8, 9, 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Technical Practice Aid (TPA)
-Number 2110
-Paragraph 6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Financial Reporting Release (FRR)
-Number 203
-Paragraph 02-03

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash
-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Cash Equivalents
-URI http://asc.fasb.org/extlink&oid=6507016

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4273-108586

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 305
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122427

+ Details

- Definition

Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 140
-Paragraph 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 2-6
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5, 6, 16-19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 20
-Subparagraph a(2)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 96-16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 97-2
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 3A
-Section 02, 03

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph k
-Article 1

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 4
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 860
-SubTopic 40
-Section 45
-URI http://asc.fasb.org/section&trid=2197723

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6921930&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.3A-02)
-URI http://asc.fasb.org/extlink&oid=6959686&loc=d3e355033-122828

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2196966

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 45
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6382870&loc=d3e33801-111570

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 325
-SubTopic 20
-URI http://asc.fasb.org/subtopic&trid=2197087

+ Details

- Definition

Disclosure of accounting policy for property, plant and equipment which may include the basis of such assets, depreciation methods used and estimated useful lives, the entity's capitalization policy, including its accounting treatment for costs incurred for repairs and maintenance activities, whether such asset balances include capitalized interest and the method by which such is calculated, how disposals of such assets are accounted for and how impairment of such assets is assessed and recognized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 22
-Paragraph 12, 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 13
-Subparagraph a
-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 5
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Chapter 9
-Section C
-Paragraph 5
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 144
-Paragraph 7
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 34
-Paragraph 8, 9
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2155824

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.13(a))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

- Definition

Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.

+ References + Details

Note 3 - Net Income per Share (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Calculation of Numerator and Denominator in Earnings Per Share [Table Text Block]

	Year Ended December 31,
(In thousands)	2011		2010		2009
Numerator
Net income	$	199,389	$	91,874	$	189,660
Add back interest expense for convertible notes, net of estimated tax of $3.0 million, $2.7 million, and $3.8 million for the years ended December 31, 2011, 2010 and 2009, respectively (see Note 12)		5,544		5,087		7,079
Income used to compute net income per diluted share	$	204,933	$	96,961	$	196,739


Denominator
Total weighted-average shares used to compute net income per basic share		139,663		126,578		119,402
Effect of dilutive stock options		13		9		18
Restricted stock outstanding		25		103		42
Assumed conversion of 2012 notes		9,790		29,870		28,809
Assumed conversion of February 2015 notes		27,950		4,229		-
Assumed conversion of 2023 notes		-		18,012		36,129
Shares used to compute net income per diluted share		177,441		178,801		184,400

Note 4 - Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	December 31, 2011						December 31, 2010
(In thousands)	Level 1		Level 2		Total		Level 1		Level 2		Total
Assets:
Money market funds	$	163,368	$	-	$	163,368	$	203,318	$	-	$	203,318
Corporate debt securities		-		44,877		44,877		20,434		-		20,434
Commercial paper		-		8,996		8,996		-		7,998		7,998
U.S. government sponsored agency bonds		2,015		-		2,015		8,725		-		8,725
U.S. treasury securities		5,513		-		5,513		1,997		-		1,997
Foreign currency hedge contracts		-		6,838		6,838		-		17,763		17,763
Total	$	170,896	$	60,711	$	231,607	$	234,474	$	25,761	$	260,235

Liabilities:
Foreign currency hedge contracts	$	-	$	9,783	$	9,783	$	-	$	12,810	$	12,810

Note 5 - Cash Equivalents, Short-term and Long-term Investments (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Available-for-sale Securities Reconciliation [Table Text Block]

			Gross		Gross			Estimated
	Amortized		Unrealized		Unrealized			Fair
(In thousands)	Cost		Gains		Losses			Value
December 31, 2011:
Money market funds	$	163,368	$	-	$	-		$	163,368
Corporate debt securities		44,863		57		(43	)		44,877
Commercial paper		8,997		-		(1	)		8,996
U.S. government sponsored agency bonds		2,003		12		-			2,015
U.S. treasury securities		5,494		19		-			5,513
Total	$	224,725	$	88	$	(44	)	$	224,769

December 31, 2010:
Money market funds	$	203,318	$	-	$	-		$	203,318
Corporate debt securities		20,437		2		(5	)		20,434
Commercial paper		7,998		-		-			7,998
U.S. government sponsored agency bonds		8,727		-		(2	)		8,725
U.S. treasury securities		1,994		3		-			1,997
Total	$	242,474	$	5	$	(7	)	$	242,472

Fair Value, by Balance Sheet Grouping [Table Text Block]

	December 31,
		2011		2010
Classification on Consolidated Balance Sheets:
Cash equivalents	$	165,367	$	205,817
Short-term investments		42,301		34,658
Long-term investments		17,101		1,997
Total	$	224,769	$	242,472

Investments Classified by Contractual Maturity Date [Table Text Block]

Available-For-Sale Debt Securities by Contractual Maturity	December 31, 2011				December 31, 2010
(In thousands)	Amortized Cost		Fair Value		Amortized Cost		Fair Value
Less than one year	$	44,262	$	44,300	$	37,162	$	37,157
Greater than one year but less than five years		17,095		17,101		1,994		1,997
Total	$	61,357	$	61,401	$	39,156	$	39,154

- Definition

Tabular disclosure of the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments, assets, and liabilities. Such certain disclosures about the financial instruments, assets, and liabilities include: (1) the fair value of the required items together with their carrying amounts (as appropriate) and (2) the methodology and assumptions used in developing such estimates of fair value.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 14
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15
-Subparagraph b-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32
-Subparagraph a, c(1), c(2), c(3), d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 18
-Subparagraph c(2), d, e, f
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 19
-Subparagraph a, b, c(1), d(1)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13433-108611

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13467-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6947722&loc=d3e13476-108611

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6925170&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6447952&loc=d3e13220-108610

+ Details

Note 6 - Foreign Currency Hedging (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Derivative Instruments [Table Text Block]

				December 31, 2011					December 31, 2010
Eurodollar Forward Contracts				(in thousands)					(in thousands)

Currency	Settlement Price ($ per Eurodollar)		Type	Notional Amount		Fair Value			Notional Amount		Fair Value
Eurodollar		1.400	Sell Eurodollar	$	25,150	$	1,837		$	137,179	$	6,740
Eurodollar		1.200	Sell Eurodollar		117,941		(9,783	)		117,941		(12,810	)
Total				$	143,091	$	(7,946	)	$	255,120	$	(6,070	)

Eurodollar Option Contracts

Currency	Strike Price ($ per Eurodollar)		Type	Notional Amount		Fair Value		Notional Amount		Fair Value
Eurodollar		1.510	Purchased call option	$	27,126	$	-	$	147,957	$	772
Eurodollar		1.315	Purchased call option		129,244		5,001		129,244		10,251
Total				$	156,370	$	5,001	$	277,201	$	11,023

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]

		Fair Value (In thousands)
Cash Flow Hedge	Location	December 31, 2011		December 31, 2010
Eurodollar contracts, net	Prepaid and other current assets	$	1,837	$	5,946
Eurodollar contracts, net	Accrued liabilities		4,134		-
Eurodollar contracts, net	Other long-term liabilities		648		993

- Definition

Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579245-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5624171-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41678-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n)(2))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41638-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5580258-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6935481&loc=SL5579240-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41641-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6935481&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

+ Details

Note 7 - Prepaid and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2011

	December 31,
(In thousands)	2011		2010
Non-recourse Notes issuance costs	$	1,226	$	3,362
Foreign currency exchange		1,837		5,946
Prepaid taxes		8,297		8,307
Other		654		445
Total	$	12,014	$	18,060

Note 8 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2011

Property, Plant and Equipment [Table Text Block]

	December 31,
(In thousands)	2011			2010
Leasehold improvements	$	112		$	112
Computer and office equipment		8,989			8,989
Furniture and fixtures		38			38
Total		9,139			9,139
Less accumulated depreciation and amortization		(9,117	)		(9,059	)
Property and equipment, net	$	22		$	80

Note 9 - Other Assets (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Other Assets, Noncurrent [Table Text Block]

	December 31,
(In thousands)	2011		2010

2012 Notes issuance costs	$	-	$	683
February 2015 Notes issuance costs		3,208		4,226
May 2015 Notes issuance costs		4,134		-
Non-recourse Notes issuance costs		-		2,397
Other		12		-
Total	$	7,354	$	7,306

Note 10 - Accrued Liabilities (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Accrued Liabilities [Table Text Block]

	December 31,
(In thousands)	2011		2010

Compensation	$	1,341	$	349
Interest		3,351		2,794
Deferred revenue		1,713		1,713
Foreign currency hedge		4,134		-
Dividend payable		52		20
Other		1,018		2,328
Total	$	11,609	$	7,204

Note 11 - Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

(In thousands)
2012	$	176
2013		83
Total	$	259

Note 12 - Convertible and Non-Recourse Notes (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Debt [Table Text Block]

(In thousands)	2012 Notes			February 2015 Notes		May 2015 Notes		Non-recourse Notes			Total
Balance at December 31, 2010	$	133,464		$	176,964	$	-	$	204,270		$	514,698
Issuance		-			-		136,313		-			136,313
Payment		-			-		-		(110,900	)		(110,900	)
Repurchase		(133,464	)		-		-		-			(133,464	)
Discount amortization		-			699		2,639		-			3,338
Balance at December 31, 2011	$	-		$	177,663	$	138,952	$	93,370		$	409,985

Fair value (1)	$	-		$	191,475	$	156,123	$	95,237		$	442,835

(In thousands)	December 31, 2011
Principal amount of the May 2015 Notes	$	155,250
Unamortized discount of liability component		(16,298	)
Net carrying value of the May 2015 Notes	$	138,952

Schedule of Interest Expense on May 2015 Notes [Table Text Block]

	For the Period May 16 to
(In thousands)	December 31, 2011
Contractual coupon interest	$	3,639
Amortization of debt issuance costs		727
Amortization of debt discount		2,639
Total	$	7,005

Schedule of Maturities of Long-term Debt [Table Text Block]

	February		May
	2015		2015		Non-recourse
(In thousands)	Notes		Notes		Notes (1)		Total
2012	$	-	$	-	$	93,370	$	93,370
2013		-		-		-		-
2014		-		-		-		-
2015		180,000		155,250		-		335,250
Total	$	180,000	$	155,250	$	93,370	$	428,620

Note 13 - Other Long-Term Liabilities (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Other Assets and Other Liabilities [Table Text Block]

	December 31,
(In thousands)	2011		2010
Accrued lease liability	$	10,700	$	10,700
Accrued legal settlement		-		27,500
Uncertain tax position		12,774		12,213
Foreign currency hedge		648		993
Total	$	24,122	$	51,406

Note 14 - Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Common Stock Activity Available Under Share Based Compensation Plans [Table Text Block]

					Total Shares of		Total Shares of
	Total Shares of		Total Shares of		Common Stock		Common Stock
	Common Stock		Common Stock		Subject to		Available for
Title of Plan	Authorized		Issued		Outstanding Awards		Grant
2005 Equity Incentive Plan(1)		5,200,000		490,143		-		4,709,857
2002 Outside Directors Stock Option Plan(2)		157,000		140,750		16,250		-
1999 Non-statutory Stock Option Plan(2)		5,075,707		4,966,183		109,524		-
1999 Stock Option Plan(2)		3,758,719		3,653,150		105,569		-

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	2011					2010					2009

				Weighted-					Weighted-					Weighted-
	Number of			Average		Number of			Average		Number of			Average
	shares			Exercise		shares			Exercise		shares			Exercise
	(in thousands)			Price		(in thousands)			Price		(in thousands)			Price
Outstanding at beginning of year		274		$	17.25		1,564		$	19.82		5,776		$	18.04
Exercised		-			-		-			-		(213	)		6.57
Forfeited		(43	)		20.67		(1,290	)		20.36		(3,999	)		17.96
Outstanding at end of year		231			16.62		274			17.25		1,564			19.82
Exercisable at end of year		231			16.62		274			17.25		1,543			20.01

Schedule of Cash Proceeds Received from Share-based Payment Awards [Table Text Block]

	Year Ended December 31,
(In thousands)	2011		2010		2009
Cash received	$	-	$	-	$	1,402
Aggregate intrinsic value	$	-	$	-	$	326

Schedule of Share-based Compensation, Restricted Stock Units Award Activity [Table Text Block]

	2011					2010					2009
	Number of shares (in thousands)			Weighted- average grant-date fair value per share		Number of shares (in thousands)			Weighted- average grant-date fair value per share		Number of shares (in thousands)			Weighted- average grant-date fair value per share
Nonvested at beginning of year		40		$	5.05		148		$	6.54		-		$	-
Awards granted		155			6.15		40			5.05		159			6.54
Awards vested		(40	)		5.05		(148	)		6.54		(5	)		6.43
Forfeited		(18	)		6.59		-			-		(6	)		6.66
Nonvested at end of year		137			6.09		40			5.05		148			6.54

Note 16 - Customer Concentration (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Entity Wide Information Revenue From External Customers by Products and Services [TableTextBlock]

	Year Ended December 31,
	2011			2010			2009
Licensees
Genentech, Inc. (Genentech)		86	%		86	%		71	%
Elan Corporation, Plc (Elan)		12	%		10	%		9	%
MedImmune, Inc. (MedImmune)		0	%		0	%		13	%

Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]

	Year Ended December 31,
(In thousands)	2011		2010		2009
United States	$	137,269	$	130,070	$	154,706
Europe		224,472		213,677		160,743
Other		300		1,228		2,735
Total revenues	$	362,041	$	344,975	$	318,184

Note 17 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Year Ended December 31.
(In thousands)	2011		2010			2009
Current income tax expense
Federal	$	83,569	$	91,325		$	87,402
State		1		11			(573	)
Total current		83,570		91,336			86,829

Deferred income tax (benefit)		24,469		(32,840	)		3,796
Total provision	$	108,039	$	58,496		$	90,625

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Year Ended December 31,
(In thousands)	2011		2010		2009
Tax at U.S. statutory rate on income before income taxes	$	107,600	$	52,630	$	98,100
Change in valuation allowance		-		296		4,891
State taxes		1		11		(573	)
Net operating loss re-establishment		-		-		(9,174	)
Non-deductible loss on retirement or conversion of convertible notes		-		4,960		-
Other		438		599		(2,619	)
Total	$	108,039	$	58,496	$	90,625

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	December 31,
(In thousands)	2011			2010
Deferred tax assets:
Net operating loss carryforwards	$	7,308		$	7,930
Research and other tax credits		5,743			5,743
Intangible assets		7,403			8,952
Stock-based compensation		273			339
Reserves and accruals		10,087			32,541
Deferred revenue		600			599
Unrealized loss on foreign currency hedge contracts		1,031			-
Other		974			506
Total deferred tax assets		33,419			56,610
Valuation allowance		(10,930	)		(10,930	)
Total deferred tax assets, net of valuation allowances		22,489			45,680
Deferred tax liabilities:
Deferred gain on repurchase of convertible notes		(954	)		(1,079	)
Unrealized gain on foreign currency hedge contracts		-			(2,079	)
Total deferred tax liabilities		(954	)		(3,158	)
Net deferred tax assets	$	21,535		$	42,522

Summary of Income Tax Contingencies [Table Text Block]

	December 31,
(In thousands)	2011		2010
Balance at the beginning of the year	$	23,061	$	23,116
Expiration of statute of limitations for the assessment of taxes		-		(55	)
Balance at the end of the year	$	23,061	$	23,061

- Definition

Tabular disclosure of tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities (i.e., uncertain tax positions) and other types of income tax contingencies, including: (1) the policy on classification of interest and penalties; (2) a tabular reconciliation of the total amounts of unrecognized tax benefits at the beginning and end of the period; the total amount(s) of: (3) unrecognized tax benefits that, if recognized, would affect the effective tax rate, and (4) interest and penalties recognized in each of the income statement and balance sheet; (5) for positions for which it is reasonably possible that the total amounts unrecognized will significantly change within 12 months of the reporting date the: (i) nature of the uncertainty, (ii) nature of the event that could occur that would cause the change, and (iii) an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made; and (6) a description of tax years that remain subject to examination by major tax jurisdictions.

+ References + Details

Note 20 - Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Dec. 31, 2011

Schedule of Quarterly Financial Information [Table Text Block]

	2011 Quarter Ended
(In thousands, except per share data)	December 31		September 30		June 30		March 31
Revenues	$	72,808	$	83,770	$	122,127	$	83,336
Net income	$	38,942	$	45,916	$	69,986	$	44,545
Net income per basic share	$	0.28	$	0.33	$	0.50	$	0.32
Net income per diluted share	$	0.24	$	0.28	$	0.38	$	0.25

	2010 Quarter Ended
(In thousands, except per share data)	December 31			September 30		June 30		March 31
Revenues	$	76,129		$	86,442	$	120,343	$	62,061
Net income	$	(24,460	)	$	40,189	$	50,138	$	26,007
Net income per basic share	$	(0.18	)	$	0.32	$	0.42	$	0.22
Net income per diluted share	$	(0.18	)	$	0.24	$	0.30	$	0.15

Note 1 - Organization and Business (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Royalty Revenue	$ 351,641	$ 343,475	$ 305,049

Note 2 - Summary of Significant Accounting Policies (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Leaseholds and Leasehold Improvements [Member]
Property, Plant and Equipment, Estimated Useful Lives		Shorterofassetlifeortermoflease
Maximum total annual milestone payments		1.00%
Comprehensive Income (Loss) Note [Text Block]		Comprehensive Income (Loss) Comprehensive income (loss) comprises net income adjusted for other comprehensive income (loss), which includes the changes in unrealized gains and losses on Eurodollar contracts and changes in unrealized gains and losses on our investments in available-for-sale securities, if any, which are excluded from our net income. The components and accumulated balances of comprehensive income (loss) were:
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion		$ 1,900,000		$ 0
Unrealized Gain (Loss) on Cash Flow Hedging Instruments			$ 3,200,000
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	$ (1,000)	$ 29,000	$ 1,000	$ 0
Description of New Accounting Pronouncements Not yet Adopted [Text Block]		Recent Accounting Pronouncements In June 2011, the Financial Accounting Standards Board (FASB) issued accounting standard update (ASU) 2011-05, eliminating the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The update requires presentation for items of net income and other comprehensive income either in one continuous statement or in two separate, but consecutive, statements. Additionally, this ASU includes a new requirement to show reclassification adjustments from other comprehensive income to net income on the face of the statement. Except for, the new requirement to show reclassification adjustments from other comprehensive income to income on the face of the income statement, this guidance is required for our first quarter of 2012 with retrospective application also required. We do not expect this guidance to have a material impact on our financial statements.
Computer and Office Equipment [Member]
Property, Plant and Equipment, Useful Life, Average		3
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life, Average		7

Note 3 - Net Income per Share (Detail) - shares shares in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Due 2012 [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.00%
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0.2	0.3	2.5
Convertible May 2015 Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13.3
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13.3
Purchased Call Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13.3
Due February 2015 [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.875%
Due 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage	2.75%
Due May 2015 [Member]
Debt Instrument, Interest Rate, Stated Percentage		3.75%

Note 3 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share - USD ($) shares in Thousands, $ in Thousands	2 Months Ended	12 Months Ended
	Feb. 29, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Stock Options [Member]
Denominator
Incremental common shares attributable to share based payment arrangements		13	9	18
Restricted Stock [Member]
Denominator
Incremental common shares attributable to share based payment arrangements		25	103	42
Due 2012 [Member]
Denominator
Assumed conversion of debt notes (in shares)		9,790	29,870	28,809
Due February 2015 [Member]
Denominator
Assumed conversion of debt notes (in shares)		27,950	4,229
Due 2023 [Member]
Denominator
Assumed conversion of debt notes (in shares)			18,012	36,129
Net income (in Dollars)		$ 199,389	$ 91,874	$ 189,660
Add back interest expense for convertible notes, net of estimated tax of $3.0 million, $2.7 million, and $3.8 million for the years ended December 31, 2011, 2010 and 2009, respectively (see Note 12) (in Dollars)		5,544	5,087	7,079
Income used to compute net income per diluted share (in Dollars)		$ 204,933	$ 96,961	$ 196,739
Total weighted-average shares used to compute net income per basic share		139,663	126,578	119,402
Assumed conversion of debt notes (in shares)	27,800
Shares used to compute net income per diluted share		177,441	178,801	184,400

Note 3 - Net Income per Share (Detail) - Net Income Per Basic and Diluted Share (Parentheticals) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Estimated tax on interest expense on convertible notes	$ 3,000,000	$ 2,700,000	$ 3,800,000

Note 4 - Fair Value Measurements (Detail) - Assets and Liabilities Recorded at Fair Value - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Money Market Funds [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Available for Sale Securities at Fair Value	$ 163,368	$ 203,318
Money Market Funds [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Available for Sale Securities at Fair Value	163,368	203,318
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Available for Sale Securities at Fair Value		20,434
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Available for Sale Securities at Fair Value	44,877
Corporate Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Available for Sale Securities at Fair Value	44,877	20,434
Commercial Paper [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Available for Sale Securities at Fair Value	8,996	7,998
Commercial Paper [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Available for Sale Securities at Fair Value	8,996	7,998
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Available for Sale Securities at Fair Value	2,015	8,725
US Government Agencies Debt Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Available for Sale Securities at Fair Value	2,015	8,725
US Treasury Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Available for Sale Securities at Fair Value	5,513	1,997
US Treasury Securities [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Available for Sale Securities at Fair Value	5,513	1,997
Derivative Financial Instruments, Assets [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Foreign currency hedge contracts	6,838	17,763
Derivative Financial Instruments, Assets [Member] \| Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Foreign currency hedge contracts	6,838	17,763
Fair Value, Inputs, Level 1 [Member]
Assets:
Total	170,896	234,474
Fair Value, Inputs, Level 2 [Member] \| Derivative Financial Instruments, Liabilities [Member]
Liabilities:
Foreign currency hedge contracts	9,783	12,810
Fair Value, Inputs, Level 2 [Member]
Assets:
Total	60,711	25,761
Estimate of Fair Value, Fair Value Disclosure [Member] \| Derivative Financial Instruments, Liabilities [Member]
Liabilities:
Foreign currency hedge contracts	9,783	12,810
Estimate of Fair Value, Fair Value Disclosure [Member]
Assets:
Total	231,607	260,235
Available for Sale Securities at Fair Value	$ 224,769	$ 242,472

Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	$ (1,000)	$ 29,000	$ 1,000	$ 0

- Definition

Appreciation or loss in value (before reclassification adjustment) of the total of unsold securities during the period being reported on, net of tax. Reclassification adjustments include: (1) the unrealized holding gain (loss), net of tax, at the date of the transfer for a debt security from the held-to-maturity category transferred into the available-for-sale category. Also includes the unrealized gain (loss) at the date of transfer for a debt security from the available-for-sale category transferred into the held-to-maturity category; (2) the unrealized gains (losses) realized upon the sale of securities, after tax; and (3) the unrealized gains (losses) realized upon the write-down of securities, after tax.

+ References

+ Details

Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-for-Sale Debt Securities - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Money Market Funds [Member]
Available for Sale Securities Amortized Cost	$ 163,368	$ 203,318
Available for Sale Securities Gross Unrealized Gains	0	0
Available for Sale Securities Gross Unrealized Losses	0	0
Available for Sale Securities Estimated Fair Value	163,368	203,318
Corporate Debt Securities [Member]
Available for Sale Securities Amortized Cost	44,863	20,437
Available for Sale Securities Gross Unrealized Gains	57	2
Available for Sale Securities Gross Unrealized Losses	(43)	(5)
Available for Sale Securities Estimated Fair Value	44,877	20,434
Commercial Paper [Member]
Available for Sale Securities Amortized Cost	8,997	7,998
Available for Sale Securities Gross Unrealized Gains	0	0
Available for Sale Securities Gross Unrealized Losses	(1)	0
Available for Sale Securities Estimated Fair Value	8,996	7,998
US Government Agencies Debt Securities [Member]
Available for Sale Securities Amortized Cost	2,003	8,727
Available for Sale Securities Gross Unrealized Gains	12	0
Available for Sale Securities Gross Unrealized Losses	0	(2)
Available for Sale Securities Estimated Fair Value	2,015	8,725
US Treasury Securities [Member]
Available for Sale Securities Amortized Cost	5,494	1,994
Available for Sale Securities Gross Unrealized Gains	19	3
Available for Sale Securities Gross Unrealized Losses	0	0
Available for Sale Securities Estimated Fair Value	5,513	1,997
Available for Sale Securities Amortized Cost	224,725	242,474
Available for Sale Securities Gross Unrealized Gains	88	5
Available for Sale Securities Gross Unrealized Losses	(44)	(7)
Available for Sale Securities Estimated Fair Value	$ 224,769	$ 242,472

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References + Details

Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Available-For-Sale Securities Balance Sheet Classification - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Cash equivalents	$ 165,367	$ 205,817
Short-term investments	42,301	34,658
Long-term investments	17,101	1,997
Total	$ 224,769	$ 242,472

- Definition

+ References + Details

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Company may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months.

+ References + Details

Note 5 - Cash Equivalents, Short-term and Long-term Investments (Detail) - Summary of Available-For-Sale Securities - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Less than one year	$ 44,262	$ 37,162
Less than one year	44,300	37,157
Greater than one year but less than five years	17,095	1,994
Greater than one year but less than five years	17,101	1,997
Total	61,357	39,156
Total	$ 61,401	$ 39,154

- Definition

For an unclassified balance sheet, total of debt securities categorized neither as held-to-maturity nor trading.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6379932&loc=d3e22054-111558

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26610-111562

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-Subparagraph (b)-(g)
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 6 - Foreign Currency Hedging (Detail) - USD ($)	12 Months Ended
Note 6 - Foreign Currency Hedging (Detail) - USD ($)	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Sales [Member] \| Cash Flow Hedging [Member]
Derivative Instruments, Gain (Loss) Recognized in Income, Net	$ 1,000,000	$ 5,200,000
Derivative Instruments, Loss Recognized in Other Comprehensive Income (Loss), Effective Portion	1,900,000		$ 0
Derivative Instruments, Gain Recognized in Other Comprehensive Income (Loss), Effective Portion		$ 3,200,000
Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net	18,874
Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months	$ 1,200,000

- Definition

The amount of net gains and losses recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments.

+ References + Details

Note 6 - Foreign Currency Hedging (Detail) - Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges $ in Thousands	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Foreign Exchange Forward [Member] \| Eurodollar Sell Forward Contract 1.400 [Member]
Settlemend Price ($ per Eurodollar)	1.400
Notional Amount	$ 25,150	$ 137,179
Fair Value	1,837	6,740
Notional Amount	25,150	137,179
Fair Value	$ 1,837	6,740
Foreign Exchange Forward [Member] \| Eurodollar Sell Forward Contract 1.200 [Member]
Settlemend Price ($ per Eurodollar)	1.200
Notional Amount	$ 117,941	117,941
Fair Value	(9,783)	(12,810)
Notional Amount	117,941	117,941
Fair Value	(9,783)	(12,810)
Foreign Exchange Forward [Member]
Notional Amount	143,091	255,120
Fair Value	(7,946)	(6,070)
Notional Amount	143,091	255,120
Fair Value	(7,946)	(6,070)
Foreign Exchange Option [Member] \| Eurodollar Purchased Call Option 1.510 [Member]
Notional Amount	$ 27,126	147,957
Fair Value		772
Strike Price ($ per Eurodollar)	1.510
Notional Amount	$ 27,126	147,957
Fair Value		772
Foreign Exchange Option [Member] \| Eurodollar Purchased Call Option 1.315 [Member]
Notional Amount	129,244	129,244
Fair Value	$ 5,001	10,251
Strike Price ($ per Eurodollar)	1.315
Notional Amount	$ 129,244	129,244
Fair Value	5,001	10,251
Foreign Exchange Option [Member]
Notional Amount	156,370	277,201
Fair Value	5,001	11,023
Notional Amount	156,370	277,201
Fair Value	$ 5,001	$ 11,023

Note 6 - Foreign Currency Hedging (Detail) - Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Other Assets [Member]
Eurodollar contracts, net	$ 1,837	$ 5,946
Accrued Liabilities [Member]
Foreign currency exchange contracts, net	4,134
Other Liabilities [Member]
Foreign currency exchange contracts, net	$ 648	$ 993

Note 7 - Prepaid and Other Current Assets (Detail) - Prepaid and Other Current Assets - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Other Assets [Member]
Foreign currency exchange	$ 1,837	$ 5,946
Non-recourse Notes issuance costs	1,226	3,362
Prepaid taxes	8,297	8,307
Other	654	445
Total	$ 12,014	$ 18,060

Note 8 - Property and Equipment (Detail) - Property and Equipment - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Leasehold Improvements [Member]
Property and equipment, gross	$ 112	$ 112
Computer and Office Equipment [Member]
Property and equipment, gross	8,989	8,989
Furniture and Fixtures [Member]
Property and equipment, gross	38	38
Property and equipment, gross	9,139	9,139
Less accumulated depreciation and amortization	(9,117)	(9,059)
Property and equipment, net	$ 22	$ 80

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Note 9 - Other Assets (Detail) - Other Assets - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
2012 Notes issuance costs		$ 683
February 2015 Notes issuance costs	$ 3,208	4,226
May 2015 Notes issuance costs	4,134
Non-recourse Notes issuance costs		2,397
Other	12
Total	$ 7,354	$ 7,306

Note 10 - Accrued Liabilities (Detail) - Accrued Liabilities - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Accrued Liabilities [Member]
Foreign currency hedge	$ 4,134
Compensation	1,341	$ 349
Interest	3,351	2,794
Deferred revenue	1,713	1,713
Dividend payable	52	20
Other	1,018	2,328
Total	$ 11,609	$ 7,204

- Definition

Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Note 11 - Commitments and Contingencies (Detail) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Operating Leases, Rent Expense	$ 0.2	$ 0.1	$ 0.2

Note 11 - Commitments and Contingencies (Detail) - Future Minimum Operating Lease Payments $ in Thousands	Dec. 31, 2011 USD ($)
2012	$ 176
2013	83
Total	$ 259

Note 12 - Convertible and Non-Recourse Notes (Detail)	1 Months Ended		2 Months Ended	3 Months Ended	8 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
Note 12 - Convertible and Non-Recourse Notes (Detail)	Feb. 28, 2012 USD ($)	Nov. 30, 2009 USD ($)	Feb. 29, 2012 $ / shares	Jun. 30, 2011 USD ($)	Dec. 31, 2011 USD ($) $ / shares shares	Sep. 30, 2011 USD ($) shares	Nov. 01, 2010 USD ($) $ / shares	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) shares	Dec. 31, 2009 USD ($)	Jan. 31, 2012 USD ($)	Jan. 05, 2012	May 17, 2011 USD ($)
Convertible May 2015 Notes [Member]
Debt Instrument, Face Amount					$ 155,250,000			$ 155,250,000
Proceeds from Convertible Debt								$ 149,700,000
Debt Instrument, Convertible, Conversion Ratio								135.9607
Debt Instrument, Convertible, Conversion Price (in Dollars per share) \| $ / shares					$ 7.36			$ 7.36
Debt Instrument, Interest Rate, Stated Percentage					3.75%			3.75%
Convertible notes repurchase price as a percentage of principal								100.00%
Purchased call option and warrants assumed conversion and exercise								During any fiscal quarter ending after the quarter ending June 30, 2011, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter; During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day; Upon the occurrence of specified corporate events as described further in the indenture; or At any time on or after November 1, 2014.
Debt Instrument, Convertible, Effective Interest Rate								7.50%
Debt Instrument, Unamortized Discount					$ 16,298,000			$ 16,298,000
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt								12,300,000
Noted obligation allocated to deferred tax liability								$ 6,600,000
Debt Instrument, Convertible, Remaining Discount Amortization Period					3.3			3.3
Debt Instrument, Convertible, Interest Expense					$ 7,005,000
Notes Payable					$ 138,952,000			$ 138,952,000
Face Amount [Member]
Repayments of Convertible Debt										$ 49,000,000
Proceeds from Convertible Debt								149,712,000	$ 82,039,000
Debt Instrument, Unamortized Discount													$ 18,900,000
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt								$ 11,870,000
Number of hedge counterparties					2			2
Option Indexed to Issuer's Equity, Shares (in Shares) \| shares								19,600,000
Class of Warrant or Right, Outstanding (in Shares) \| shares					27,500,000			27,500,000
Option Indexed to Issuer's Equity, Strike Price								7.36
Class of Warrant or Right, Exercise Price of Warrants or Rights					8.65			8.65
Debt Instrument, Convertible, Terms of Conversion Feature								If the share price is above $7.36, upon conversion of our May 2015 Notes, the purchased call options willoffset the share dilution, because the Company will receive shares on exercise of the purchased call options equal to the shares that the Company must deliver to the note holders. If the share price is above $8.65, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $8.65. For example, a 10% increase in the share price above $8.65 would result in the issuance of 1.9 million incremental shares upon exercise of the warrants. As our share price continues to increase, additional dilution would occur.
Purchased call options cost								$ 20,800,000
Deferred taxes on purchased call options cost								$ 7,200,000
Number of shares of common stock covered by the purchased call options purchased (in Shares) \| shares					21,100,000			21,100,000
Proceeds from Issuance of Warrants						$ 10,900,000		$ 10,868,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) \| shares					27,500,000	27,500,000		27,500,000
Debt Conversion, Converted Instrument, Amount							$ 92,000,000		111,680,000
Gains (Losses) on Extinguishment of Debt							$ 1,100,000	$ (766,000)	(17,648,000)	1,518,000
Repayments of Convertible Debt								133,851,000	108,247,000	69,953,000
Notes Payable					$ 409,985,000			409,985,000	514,698,000
Securitization of Royalties		60.00%
Convertible February 2015 Notes [Member]
Debt Instrument, Convertible, Conversion Ratio							155.396
Debt Instrument, Convertible, Conversion Price (in Dollars per share) \| $ / shares							$ 6.44
Convertible notes repurchase price as a percentage of principal							100.00%
Debt Instrument, Unamortized Discount					$ 2,300,000			$ 2,300,000
Debt Instrument, Convertible, Remaining Discount Amortization Period					3.2			3.2
Debt Conversion, Converted Instrument, Amount	$ 10,000,000								92,000,000
Debt Instrument, Increase, Additional Borrowings							$ 88,000,000
Convertible Debt							$ 180,000,000
Unamortized Debt Issuance Expense					$ 3,200,000			$ 3,200,000
Notes Payable					$ 177,663,000			$ 177,663,000	176,964,000
Non-Recourse Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		10.25%										2.875%
Debt Instrument, Convertible, Remaining Discount Amortization Period					3			3
Unamortized Debt Issuance Expense					$ 1,200,000			$ 1,200,000
Notes Payable		$ 300,000,000			$ 93,370,000			$ 93,370,000	204,270,000
Series 2012 Notes [Member]
Debt Instrument, Convertible, Conversion Ratio			155.396
Debt Instrument, Convertible, Conversion Price (in Dollars per share) \| $ / shares			$ 6.44
Debt Instrument, Interest Rate, Stated Percentage											2.875%	2.875%
Convertible Debt											$ 169,000,000
Debt Instrument, Increase (Decrease) for Period, Net				$ 133,500,000
Due 2012 [Member] \| Face Amount [Member]
Repayments of Convertible Debt										22,000,000
Due 2012 [Member]
Debt Conversion, Converted Instrument, Amount									$ 10,000
Gains (Losses) on Extinguishment of Debt				$ 800,000						800,000
Redemption price of face value (in hundredths)				100.29%
Aggregate consideration of redemption				$ 133,900,000
Debt Instrument, Convertible, Interest Expense				$ 1,000,000
Note Face Value Discount Rate Percent									0.50%
Repayments of Convertible Debt									$ 2,500,000	21,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) \| shares									1,283
Notes Payable									$ 133,464,000
Due 2023 [Member] \| Face Amount [Member]
Repayments of Convertible Debt									88,400,000
Due 2023 [Member]
Debt Conversion, Converted Instrument, Amount									111,700,000
Gains (Losses) on Extinguishment of Debt									2,400,000	700,000
Repayments of Convertible Debt									$ 104,600,000	$ 50,000,000
Debt Conversion, Converted Instrument, Shares Issued (in Shares) \| shares									20,000,000

Note 12 - Convertible and Non-Recourse Notes (Detail) - Convertible and Non-Recourse Notes - USD ($)
$ in Thousands

8 Months Ended

12 Months Ended

Dec. 31, 2011

Dec. 31, 2010

Due 2012 [Member]

Balance at December 31, 2010

$ 133,464

Repurchase

(133,464)

Balance at December 31, 2011

$ 133,464

Fair value (1)

^[1]

Convertible February 2015 Notes [Member]

Balance at December 31, 2010

176,964

Discount amortization

699

Balance at December 31, 2011

177,663

176,964

Fair value (1)

^[1]

191,475

Convertible May 2015 Notes [Member]

Issuance

136,313

Discount amortization

2,639

Balance at December 31, 2011

138,952

Fair value (1)

^[1]

156,123

Non-Recourse Notes [Member]

Balance at December 31, 2010

204,270

Payment

(110,900)

Balance at December 31, 2011

93,370

204,270

Fair value (1)

^[1]

95,237

Balance at December 31, 2010

514,698

Issuance

136,313

Payment

(110,900)

(95,730)

Repurchase

(133,464)

Discount amortization

3,338

Balance at December 31, 2011

409,985

$ 514,698

Fair value (1)

^[1]

$ 442,835

[1]	As of December 31, 2011, the fair value of the remaining payments under our convertible notes and Non-recourse Notes was estimated based on the trading value of our notes then outstanding.

Note 12 - Convertible and Non-Recourse Notes (Detail) - May 2015 Notes - USD ($) $ in Thousands	Dec. 31, 2011	May 17, 2011	Dec. 31, 2010
Convertible May 2015 Notes [Member]
Principal amount of the May 2015 Notes	$ 155,250
Unamortized discount of liability component	(16,298)
Net carrying value of the May 2015 Notes	138,952
Unamortized discount of liability component		$ (18,900)
Net carrying value of the May 2015 Notes	$ 409,985		$ 514,698

Note 12 - Convertible and Non-Recourse Notes (Detail) - Interest Expense for the May 2015 Notes - USD ($) $ in Thousands	8 Months Ended	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Convertible May 2015 Notes [Member]
Contractual coupon interest	$ 3,639
Amortization of debt issuance costs	727
Amortization of debt discount	2,639	$ 2,639
Total	$ 7,005
Amortization of debt issuance costs		5,386	$ 1,682	$ 2,159
Amortization of debt discount		$ 3,338

Note 12 - Convertible and Non-Recourse Notes (Detail) - Future Minimum Principal Payments
$ in Thousands

Dec. 31, 2011

USD ($)

Convertible February 2015 Notes [Member]

$ 0

180,000

180,000

Convertible May 2015 Notes [Member]

155,250

155,250

Non-Recourse Notes [Member]

2012

93,370

^[1]

^[1]

^[1]

^[1]

93,370

^[1]

93,370

335,250

$ 428,620

[1]	Repayment of the Non-recourse Notes is based on anticipated future royalties to be received from Genentech and the anticipated final payment date is September 2012.

Note 13 - Other Long-Term Liabilities (Detail) $ in Thousands, ؋ in Millions	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2010 AFN (؋)
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 110,800
Accrued Rent, Noncurrent	$ 10,700	$ 10,700	؋ 10.7

Note 13 - Other Long-Term Liabilities (Detail) - Other Long-Term Liabilities $ in Thousands, ؋ in Millions	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)	Dec. 31, 2010 AFN (؋)
Other Liabilities [Member]
Foreign currency hedge	$ 648	$ 993
Accrued lease liability	10,700	10,700	؋ 10.7
Accrued legal settlement		27,500
Uncertain tax position	12,774	12,213
Total	$ 24,122	$ 51,406

Note 14 - Stock-Based Compensation (Detail)	12 Months Ended
Note 14 - Stock-Based Compensation (Detail)	Dec. 31, 2011 USD ($) $ / shares shares	Dec. 31, 2010 USD ($) $ / shares shares	Dec. 31, 2009 USD ($) $ / shares shares
Directors and Employees [Member]
Allocated Share-based Compensation Expense, Net of Tax	$ 337,000	$ 662,000	$ 773,000
Restricted Stock [Member]
Allocated Share-based Compensation Expense, Net of Tax	$ 400,000	$ 600,000	$ 500,000
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Minimum	twelve
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period, Maximum	twenty-four
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value (in Dollars per share) \| $ / shares	$ 800,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized	$ 500,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition	10
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number (in Shares) \| shares	136,507	40,000	148,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	$ 45,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term	2.33
Closing Market Price of Company's Stock (in Dollars per share) \| $ / shares	$ 6.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period (in Shares) \| shares	43,000	1,290,000	3,999,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price (in Dollars per share) \| $ / shares	$ 20.67	$ 20.36	$ 17.96
Non-Employees [Member]
Allocated Share-based Compensation Expense, Net of Tax	$ 50,000	$ 0	$ 48,000

Note 14 - Stock-Based Compensation (Detail) - Shares of Company Common Stock Available Under Share-Based Plans - shares

12 Months Ended

Dec. 31, 2011

Dec. 31, 2010

Dec. 31, 2009

Dec. 31, 2008

2005 Equity Incentive Plan [Member]

Shares of Common Stock Authorized Under Plan

^[1]

5,200,000

Total Shares of Common Stock Issued Under Plan

^[1]

490,143

Total Shares of Common Stock Subject to Outstanding Awards Under Plan

^[1]

Total Shares of Common Stock Available for Grant Under Plan

^[1]

4,709,857

2002 Outside Directors Stock Option Plan [Member]

Shares of Common Stock Authorized Under Plan

^[2]

157,000

Total Shares of Common Stock Issued Under Plan

^[2]

140,750

Total Shares of Common Stock Subject to Outstanding Awards Under Plan

^[2]

16,250

Total Shares of Common Stock Available for Grant Under Plan

^[2]

1999 Non-statutory Stock Option Plan [Member]

Shares of Common Stock Authorized Under Plan

^[2]

5,075,707

Total Shares of Common Stock Issued Under Plan

^[2]

4,966,183

Total Shares of Common Stock Subject to Outstanding Awards Under Plan

^[2]

109,524

Total Shares of Common Stock Available for Grant Under Plan

^[2]

1999 Stock Option Plan [Member]

Shares of Common Stock Authorized Under Plan

^[2]

3,758,719

Total Shares of Common Stock Issued Under Plan

^[2]

3,653,150

Total Shares of Common Stock Subject to Outstanding Awards Under Plan

^[2]

105,569

Total Shares of Common Stock Available for Grant Under Plan

^[2]

Total Shares of Common Stock Subject to Outstanding Awards Under Plan

231,000

274,000

1,564,000

5,776,000

[1]	As of December 31, 2011, there were 136,507 shares of unvested restricted stock awards outstanding.
[2]	Plan terminated in 2009, subject to options outstanding under the plan.

Note 14 - Stock-Based Compensation (Detail) - Stock Option Activity - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Outstanding at beginning of year	274	1,564	5,776
Outstanding at beginning of year (in Dollars per share)	$ 17.25	$ 19.82	$ 18.04
Exercised	0	0	(213)
Exercised (in Dollars per share)	$ 0	$ 0	$ 6.57
Forfeited	(43)	(1,290)	(3,999)
Forfeited (in Dollars per share)	$ 20.67	$ 20.36	$ 17.96
Outstanding at end of year	231	274	1,564
Outstanding at end of year (in Dollars per share)	$ 16.62	$ 17.25	$ 19.82
Exercisable at end of year	231	274	1,543
Exercisable at end of year (in Dollars per share)	$ 16.62	$ 17.25	$ 20.01

Note 14 - Stock-Based Compensation (Detail) - Additional Information Regarding Our Options Exercised $ in Thousands	12 Months Ended
	Dec. 31, 2009 USD ($)
Cash received	$ 1,402
Aggregate intrinsic value	$ 326

- Definition

The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph A240
-Subparagraph i
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 18
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 19
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Financing Activities
-URI http://asc.fasb.org/extlink&oid=6513228

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (j)
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Note 14 - Stock-Based Compensation (Detail) - Restricted Stock Activity - $ / shares	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Nonvested at beginning of year	40,000	148,000
Nonvested at beginning of year (in Dollars per share)	$ 5.05	$ 6.54
Nonvested at end of year	136,507	40,000	148,000
Nonvested at end of year (in Dollars per share)	$ 6.09	$ 5.05	$ 6.54
Awards granted	155,000	40,000	159,000
Awards granted (in Dollars per share)	$ 6.15	$ 5.05	$ 6.54
Awards vested	(40,000)	(148,000)	(5,000)
Awards vested (in Dollars per share)	$ 5.05	$ 6.54	$ 6.43
Forfeited	(18,000)	0	(6,000)
Forfeited (in Dollars per share)	$ 6.59	$ 0	$ 6.66

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References + Details

Note 15 - Cash Dividends (Detail) - USD ($)		12 Months Ended
Note 15 - Cash Dividends (Detail) - USD ($)	Oct. 02, 2010	Dec. 31, 2011	Apr. 02, 2011	Dec. 31, 2012	Jan. 18, 2012	Feb. 25, 2011	Dec. 31, 2010	Jan. 31, 2010
Special Cash Dividends Declared [Member]
Dividends Payable, Amount Per Share (in Dollars per share)								$ 0.50
Dividends, Cash (in Dollars)	$ 69,800,000		$ 59,900,000
Dividends Payable, Amount Per Share (in Dollars per share)					$ 0.15	$ 0.15
Dividends Payable Dates To be Paid Day Month And Year				March14, June14,September14 and December14 of 2012		March15, June15,September15 and December15 of 2011
Dividends Payable Dates of Record, Day, Month and Year				March7, June7,September7 and December 7 of 2012		March8, June8,September8 and December8 of 2011
Dividends, Cash (in Dollars)		$ 83,800,000
Restricted Stock [Member]
Dividends Payable, Amount (in Dollars)							$ 20,000

Note 16 - Customer Concentration (Detail)	Dec. 31, 2011
Minimum threshold percent of total royalty income requiring disclosure by licensee by product name (in hundredths)	10.00%

Note 16 - Customer Concentration (Detail) - Percentage of Total Revenue From Licenses Over 10% of Revenue	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Genentech [Member]
Licensees
Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths)	86.00%	86.00%	71.00%
Elan [Member]
Licensees
Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths)	12.00%	10.00%	9.00%
MedImmune [Member]
Licensees
Minimum threshold percent of total royalty income requiring disclosure by license by product name - year to date (in hundredths)	0.00%	0.00%	13.00%

Note 16 - Customer Concentration (Detail) - Total Revenues by Geographic Area - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Europe [Member]
Foreign Revenues	$ 224,472	$ 213,677	$ 160,743
Other Geographic Areas [Member]
Foreign Revenues	300	1,228	2,735
United States	137,269	130,070	154,706
Total revenues	$ 362,041	$ 344,975	$ 318,184

Note 17 - Income Taxes (Detail) - USD ($)	12 Months Ended		132 Months Ended
Note 17 - Income Taxes (Detail) - USD ($)	Dec. 31, 2023	Dec. 31, 2011	Dec. 31, 2022	Dec. 31, 2010	Dec. 31, 2009
Operating Loss Carryforwards		$ 42,900,000		$ 44,700,000
Operating Loss Carryforwards, Expiration Dates		2023
Operating Loss Carryforwards, Limitations on Use	$1.3 for the year ended December31, 2023		We have an annual limitation on the use of our federal operating losses of $1.8 million for each of the years ended December31, 2012 to 2022
Operating Loss Carryforwards, Valuation Allowance		$ 22,000,000
Unrecognized Tax Benefits		23,061,000		23,061,000	$ 23,116,000
Unrecognized Tax Benefits that Would Impact Effective Tax Rate		12,200,000
Unrecognized Tax Benefits Resulting in Adjustment to Deferred Tax Assets		10,900,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		$ 500,000		$ 26,000	$ 400,000

- Definition

The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 43
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 17
-Subparagraph e
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 48
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 30
-Paragraph 5
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=6907311&loc=d3e30536-109315

+ Details

Note 17 - Income Taxes (Detail) - Provision for Income Taxes - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Current income tax expense
Federal	$ 83,569	$ 91,325	$ 87,402
State	1	11	(573)
Total current	83,570	91,336	86,829
Deferred income tax (benefit)	24,469	(32,840)	3,796
Total provision	$ 108,039	$ 58,496	$ 90,625

- Definition

The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted federal tax law to the domestic taxable Income or Loss from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Paragraph Question 1-7

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The component of income tax expense for the period representing amounts of income taxes paid or payable (or refundable) for the period for all income tax obligations as determined by applying the provisions of relevant enacted tax laws to relevant amounts of taxable Income or Loss from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

+ Details

- Definition

The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted state and local tax law to relevant amounts of taxable Income or Loss from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

+ Details

- Definition

The component of total income tax expense for the period comprised of the increase (decrease) during the period in the entity's domestic deferred tax assets and liabilities attributable to continuing operations as determined by applying the provisions of the federally enacted tax law.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Deferred Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6510177

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Subsection 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 8, 16, 17, 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 17 - Income Taxes (Detail) - Reconciliation of the Income Tax Provision Computed Using the U.S. Statutory Federal Income Tax Rate - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Tax at U.S. statutory rate on income before income taxes	$ 107,600	$ 52,630	$ 98,100
Change in valuation allowance		296	4,891
State taxes	1	11	(573)
Net operating loss re-establishment			(9,174)
Non-deductible loss on retirement or conversion of convertible notes		4,960
Other	438	599	(2,619)
Total	$ 108,039	$ 58,496	$ 90,625

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to pretax Income or Loss from continuing operations; income tax expense or benefit may include interest and penalties on tax uncertainties based on the entity's accounting policy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 48
-Paragraph 15, 16, 19
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45, 46
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32672-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a),(b)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 45
-Paragraph 25
-URI http://asc.fasb.org/extlink&oid=6907571&loc=d3e32247-109318

+ Details

Note 17 - Income Taxes (Detail) - Deferred Tax Assets and Liabilities - USD ($) $ in Thousands	Dec. 31, 2011	Dec. 31, 2010
Deferred tax assets:
Net operating loss carryforwards	$ 7,308	$ 7,930
Research and other tax credits	5,743	5,743
Intangible assets	7,403	8,952
Stock-based compensation	273	339
Reserves and accruals	10,087	32,541
Deferred revenue	600	599
Unrealized loss on foreign currency hedge contracts	1,031
Other	974	506
Total deferred tax assets	33,419	56,610
Valuation allowance	(10,930)	(10,930)
Total deferred tax assets, net of valuation allowances	22,489	45,680
Deferred tax liabilities:
Deferred gain on repurchase of convertible notes	(954)	(1,079)
Unrealized gain on foreign currency hedge contracts		(2,079)
Total deferred tax liabilities	(954)	(3,158)
Net deferred tax assets	$ 21,535	$ 42,522

Note 17 - Income Taxes (Detail) - Unrecognized Tax Benefits $ in Thousands	12 Months Ended
	Dec. 31, 2010 USD ($)
Balance at the beginning of the year	$ 23,116
Balance at the end of the year	23,061
Expiration of statute of limitations for the assessment of taxes	$ (55)

Note 18 - Legal Proceedings (Detail) $ in Millions	1 Months Ended		2 Months Ended	12 Months Ended	13 Months Ended
Note 18 - Legal Proceedings (Detail) $ in Millions	Feb. 09, 2012 USD ($)	Feb. 02, 2011 USD ($)	Feb. 15, 2011 USD ($)	Dec. 31, 2011 USD ($)	Feb. 09, 2012 USD ($)	Jul. 07, 2011
Europe [Member]
RoyaltyRevenueGeographicConcentration				33.00%
MedImmune [Member]
Payments for Legal Settlements	$ 27.5		$ 65.0		$ 92.5
Gain Contingency, Unrecorded Amount				$ 1,000.0
Royalty Rate				3.75%
Number of Genentech's Claims Dismissed by Court						2
Number of PDL's Claims Upheld by Court				4
Number of PDL's claims for relief relating to the 2003 settlement agreement				5
Number of PDL's claims dismissed by the court				1
UCB Pharma S.A. [Member]
Proceeds from Legal Settlements		$ 10.0

Note 19 - Subsequent Event (Detail) $ / shares in Units, shares in Millions	1 Months Ended		2 Months Ended	10 Months Ended	12 Months Ended
	Feb. 28, 2012 USD ($)	Jan. 31, 2012 USD ($)	Feb. 29, 2012 $ / shares shares	Nov. 01, 2010 USD ($) $ / shares	Dec. 31, 2010 USD ($)	Feb. 02, 2012 USD ($)	Jan. 05, 2012
Convertible February 2015 Notes [Member]
Percentage of Convertible Notes Exchanged							93.90%
Convertible Debt				$ 180,000,000
Incentive Fee Per Thousand to Convert Debt		$ 5.00
Induced Conversion of Convertible Debt Expense		$ 800,000
Debt Conversion, Converted Instrument, Amount	$ 10,000,000				$ 92,000,000
Convertible Notes Payable						$ 1,000,000
Debt Instrument, Convertible, Conversion Ratio				155.396
Debt Instrument, Convertible, Conversion Price (in Dollars per share) \| $ / shares				$ 6.44
Debt Conversion, Converted Instrument, Amount				$ 92,000,000	$ 111,680,000
Incremental Common Shares Attributable to Conversion of Debt Securities (in Shares) \| shares			27.8
Series 2012 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage		2.875%					2.875%
Convertible Debt		$ 169,000,000
Convertible Notes Payable						$ 179,000,000
Debt Instrument, Convertible, Conversion Ratio			155.396
Debt Instrument, Convertible, Conversion Price (in Dollars per share) \| $ / shares			$ 6.44

Note 20 - Quarterly Financial Data (Unaudited) (Detail) - Quarterly Financial Data (Unaudited) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009
Quarter Ending December 31 [Member]
Revenues	$ 72,808	$ 76,129
Net income	$ 38,942	$ (24,460)
Net income per basic share (in Dollars per share)	$ 0.28	$ (0.18)
Net income per diluted share (in Dollars per share)	$ 0.24	$ (0.18)
Quarter Ending September 30 [Member]
Revenues	$ 83,770	$ 86,442
Net income	$ 45,916	$ 40,189
Net income per basic share (in Dollars per share)	$ 0.33	$ 0.32
Net income per diluted share (in Dollars per share)	$ 0.28	$ 0.24
Quarter Ending June 30 [Member]
Revenues	$ 122,127	$ 120,343
Net income	$ 69,986	$ 50,138
Net income per basic share (in Dollars per share)	$ 0.50	$ 0.42
Net income per diluted share (in Dollars per share)	$ 0.38	$ 0.30
Quarter Ending March 31 [Member]
Revenues	$ 83,336	$ 62,061
Net income	$ 44,545	$ 26,007
Net income per basic share (in Dollars per share)	$ 0.32	$ 0.22
Net income per diluted share (in Dollars per share)	$ 0.25	$ 0.15
Revenues	$ 362,041	$ 344,975	$ 318,184
Net income	$ 199,389	$ 91,874	$ 189,660
Net income per basic share (in Dollars per share)	$ 1.43	$ 0.73	$ 1.59
Net income per diluted share (in Dollars per share)	$ 1.15	$ 0.54	$ 1.07

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 20

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 7
-Paragraph 18

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6920599&loc=d3e1252-109256

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=6945512&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Article 5
-Section 03
-Paragraph 19

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

+ Details